You are on page 1of 22

Perspective

pubs.acs.org/jmc

Modulating Mineralocorticoid Receptor with Non-steroidal
Antagonists. New Opportunities for the Development of Potent and
Selective Ligands without Off-Target Side Effects
Mercedes Martín-Martínez,*,† Felipe L. Pérez-Gordillo,† Diego Á lvarez de la Rosa,‡ Yoel Rodríguez,§,⊥
Guillermo Gerona-Navarro,∥ Rosario González-Muñiz,† and Ming-Ming Zhou§

Instituto de Química Médica (IQM-CSIC), Juan de la Cierva, 3, 28006 Madrid, Spain

Institute of Biomedical Technologies and Department of Physiology, Campus de Ciencias de la Salud, Facultad de Medicina,
Universidad de La Laguna, 38204 Tenerife, Spain
See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.

§
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States

Department of Natural Sciences, Hostos Community College of CUNY, 475 Grand Concourse, Bronx, New York 10451, United
Downloaded via UNIV DE BARCELONA on October 3, 2018 at 01:30:18 (UTC).

States

Department of Chemistry, Brooklyn College, 2900 Bedford Avenue, Brooklyn, New York 11210, United States

ABSTRACT: Steroidal mineralocorticoid receptor (MR)
antagonists are used for treatment of a range of human
diseases, but they present challenging issues of complex
chemical synthesis, undesirable physical properties, and poor
selectivity along with unwanted side effects. Therefore, there is
a great interest in the discovery of non-steroidal ligands able to
bind to the ligand-binding domain of the MR and recruit
different co-regulators to produce tissue-specific therapeutic
effects. Several academic groups and pharmaceutical companies
have been developing a series of non-steroidal ligands that consist of different chemical scaffolds, yielding MR antagonists
currently evaluated in clinical studies for the treatment of congestive heart failure, hypertension, or diabetic nephropathy. The
main focus of this Perspective is to review the reported structure−activity relationships of the different series of compounds, as
well as the structural studies that contribute to a better understanding of the receptor active site and are also helpful for
optimization processes.

■ INTRODUCTION
The mineralocorticoid receptor (MR) is a member of the
include, but are not limited to, (a) morphological remodeling in
epithelia such as the kidney and distal colon; (b) direct
nuclear receptor superfamily of transcription factors.1 The main modulation of cardiac and vascular function and remodeling;
physiological role of the MR is to transduce the effects of (c) regulation of nervous system activity and its control of the
aldosterone, a steroid hormone produced in the adrenal gland cardiovascular and renal systems; (d) regulation of energy
in response to intravascular volume depletion or hyperkalemia. metabolism; and (e) immune responses. Underlying the wide
Aldosterone interaction with MR initiates homeostatic variety of MR physiological and pathological roles are two
responses that oppose the original imbalance. During volume factors. First, the MR is widely expressed in different tissues.
depletion, aldosterone/MR increases renal NaCl reabsorption Second, glucocorticoids such as cortisol can also act as agonists
by activation of the epithelial Na+ channel (ENaC) and the of the receptor,1 particularly in those tissues that lack the
Na+/Cl− co-transporter (NCC). In hyperkalemia, aldosterone- enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2),
mediated ENaC activation provides an electrical gradient in the which metabolizes cortisol to cortisone, an inactive metabolite.4
renal tubule that potentiates K+ and H+ excretion. Consistent As all other members of the steroid receptor family, the MR
with this fundamental physiological role, inherited gain- or loss- displays a modular architecture. The NH2-terminal domain
of-function mutations in MR, ENaC, and their regulatory (NTD) mediates the interaction with transcriptional co-
proteins cause genetic diseases characterized by disturbances in regulators and displays the highest level of sequence
blood pressure homeostasis and mineral metabolism.2 dissimilarity with other steroid receptors, an essential feature
In addition, during the past few years it has become apparent to determine selectivity in mineralocorticoid responses.
that MR medium- and long-term systemic actions are far wider Following the NTD in the MR primary sequence, there is a
than previously thought.3 Regulated MR function is essential central DNA binding domain (DBD) formed by two zinc
not only to blood pressure and mineral homeostasis but also to
organ and tissue differentiation and morphological and Received: July 17, 2016
functional tissue remodeling in health and disease. These Published: January 4, 2017

© 2017 American Chemical Society 2629 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

fingers. The DBD interacts with specific DNA sequences antagonists can be divided in two categories. The already
named hormone response elements (HREs). The DBD of the mentioned sexual side effects, due to the close similarity in the
MR is 90−94% identical to DBDs of other steroid receptors LBDs of MR and related steroid receptors, make it difficult to
such as glucocorticoid, progesterone, and androgen receptors, develop steroid-derived drugs with high specificity for the MR
implying that HREs recognized by them are highly similar. A over the progesterone or androgen receptors. The second
hinge domain separates the DBD from a COOH-terminal category of the MR adverse effects can be ascribed to the
portion that harbors the ligand-binding domain (LBD) and an undesired interference with aldosterone classical function in
additional region that serves a transcriptional activation regulating electrolyte homeostasis, particularly in promoting K+
function in a ligand-dependent manner. Steroid receptor excretion in the kidney tubule. Indeed, it has been observed
LBDs present moderate identity between them (50−60%), that inappropriate dosage of spironolactone can lead to
and while they allow for specific activation by different hyperkalemia, which in turn is a risk factor for cardiac
hormones, there is some degree of cross-reactivity between complications, particularly in patients with renal insufficiency.19
them. For instance, the MR shows the same affinity for On the other hand, hypokalemia also worsens outcomes in
aldosterone and for glucocorticoids such as cortisol or patients with severe heart failure, and therefore the tendency of
corticosterone (Kd = 0.5−2 nM), although the half-maximal MR antagonists to increase plasma K+ levels may be desirable
effective concentration (EC50) of aldosterone is 100-fold lower, under controlled circumstances.20 To overcome these two
which has been explained due to a much lower off-rate of types of adverse effects, the focus of MR pharmacology has
aldosterone from the MR.5 Other steroids such as progesterone shifted toward developing non-steroidal inhibitors that ideally
act as antagonists of the MR. High-resolution crystal structures would have tissue-specific properties. A third generation of MR
of the MR LBD in combination with agonists 6,7 or antagonists based on non-steroidal compounds is currently
antagonists6,8,9 are available. In addition, a naturally occurring being developed, and some of these products, like the
mutant that causes pregnancy-related hypertension10 and dihydropyridine-like compound finerenone (see below), are
converts progesterone into an agonist has also been crystal- currently under clinical trials.18,21,22 In this Perspective we
lized.6,11 Therefore, a good deal of information about the examine the described non-steroidal ligands collected either in
structural determinants involved in ligand binding to the MR papers or patents. The review aims to be a useful tool for
LBD is available.12 structure−activity relationship (SAR) studies, and therefore
For many years, the main focus of drug discovery targeting includes different families of non-steroid ligands able to bind to
the MR has been on the use of its antagonist spironolactone in the MR, and several compounds within each family.
the context of primary hyperaldosteronism or as potassium-
sparing diuretics to be used in combination with loop diuretics
and thiazides.13 Spironolactone displays undesired side effects,
■ NON-STEROIDAL MINERALOCORTICOID
RECEPTOR LIGANDS
particularly producing sexual dysfunction and gynecomastia in 1. 1,4-Dihydropyridine and 1,4-Dihydro-1,6-naph-
men. In these cases, an alternative is to treat patients with thyridinamide Compounds as MR Ligands. 1,4-Dihydro-
chemically unrelated drugs such as amiloride or triamterene, pyridines (DHP) represent an interesting scaffold for the search
which target a downstream target of the MR, the epithelial of non-steroidal MR antagonis and have attracted the interest
sodium channel (ENaC).13 However, renewed interest in MR of several pharmaceutical companies.
antagonists has been triggered by a combination of new Pfizer, through a screening of its in-house collection,
findings in the last two decades. First, the realization that identified a series of DHPs, previously recognized as calcium
aldosteronism is more widespread in the human population channel blockers (CCBs), as MR antagonists.23 Among them,
than previously thought indicates that MR antagonism will nimodipine and felodipine competed for aldosterone binding
probably expand its scope. Second, it has been firmly and were only slightly less active than eplerenone. As
established that the MR is expressed outside classic aldosterone stereoselective issues affect calcium channel activity, it was
target epithelia and can be considered a ubiquitous receptor. investigated whether the CCB and the MR activities resided in
Pioneering work from Weber’s laboratory using animal models the same DHP stereoisomer. The study of the CCB-
suggested that the MR was an important mediator in the asymmetric DHP mebudipine (1a) indicated that the 4R
development of direct, blood pressure-independent heart enantiomer was responsible for the MR antagonist activity,
fibrosis and inflammation.14 This prompted a clinical trial while the 4S enantiomer had the CCB activity (Table 1.1).24 In
(RALES) where patients with severe heart failure received the agreement with this result, a cyano DHP, identified at Bayer,
aldosterone antagonist spironolactone at doses that did not showed a preference for the R configuration in its binding to
significantly affect blood pressure. The treatment quickly the MR. However, this was also the more active isomer for L-
demonstrated very beneficial effects, with significant decreases type Ca2+ channels.25 Moreover, it was also observed that the
in morbidity and mortality.15 On the other hand, the discovery cyano group at R3 position induced high selectivity against
of eplerenone, a steroid MR antagonist with improved CCB and good selectivity against other nuclear hormone
selectivity over other steroid receptors and therefore displaying receptors (NHRs).26 Based on these results, a library of DHP
less sexual side effects, triggered a second large clinical trial, was prepared to perform SAR studies. Substitution at the DHP
EPHESUS, which further demonstrated the utility of MR NH group decreased activity, suggesting a potential hydrogen
antagonism.16 Recent studies on non-epithelial aldosterone/ bond with the MR.26 Similar results were also reported by
MR effects has expanded the interest in this signaling system to Bayer.25 Regarding the aromatic phenyl ring at position 4,
related pathophysiological settings, such as the vasculature,3 small, nonpolar substituents like F, Cl, or CF3 were suitable at
oxidative stress, inflammation, and metabolic diseases related to the ortho or the para position, with a 2-chloro,4-fluorophenyl
obesity. Given the already important and expanding clinical moiety giving the best results (1b−1e, Table 1.1).26 A
applications, the obvious question is whether new MR voluminous R1 group like phenyl or benzyl decreased potency,
antagonists are needed.17,18 The main adverse effects of MR while smaller C2−C4 alkyl groups were adequate (1c).
2630 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Table 1.1. Selected Pfizer DHP MR Antagonists and Their Table 1.2. MR Activity of DHP by Bayer Pharma25,29
IC50 Values24,26

a
Gal4/LBD reporter assay in CHO-K1 cells. bc-Bu = cyclobutyl.

substituents had been analyzed at C4 position (Table 1.2),
with the fluorenyl moiety B (compound 1g) leading to an
a increase in potency with respect to the quinoline analogue
Determined using a Gal4/MR LBD (Gal4/LBD) reporter assay in 1f.25,28 Subsequent attempts to decrease 4-Ar size and
HUH7 human hepatocyte cells. bChiral resolution of 1e afforded the
R-enantiomer (IC50 = 52 nM).
lipophilicity allowed the identification of chromenone deriva-
tives (1h, Ar = C), at the cost of lower activity.25 In this latter
subseries, the potency could be restored by modulating R1 and
However, a methylene linker tethering an imidazole, 1d, R2 substituents (1i−1m).25,29 Because of the low bioavailability
triazole or tetrazole, 1e, maintained potency while increasing of 1j, the less lipophilic ethyl ester BR-4628 (R-1k) was
selectivity against other NHRs. The tetrazole derivative 1e preferred due to its favorable PK profile.25 R-1k, a potent MR
showed an in vitro pharmacokinetic (PK) profile adequate for in LBD antagonist, 160-fold more selective for the MR over the
vivo studies (CL = 14.1 mL/min/kg, T1/2 = 4.84 h). Compound AR and with low CCB activity, was considered a drug
1e was able to reduce blood pressure and renal injury in rats in candidate. Different from spironolactone and eplerenone, R-
vivo. Induced fit docking (IFD) studies of this compound 1k retained its antagonist character at the MRS810L mutant. In
suggested partial overlapping with the native corticosterone MR vivo assays in rats probed that it increased the urinary sodium/
binding pocket.26 potassium ratio in a dose-dependent manner, with effect for a
Bayer Pharma, in an ultra-high-throughput screening of dose as low as 1 mg/kg.27 R-1k also prevented the aldosterone-
almost one million compounds, found a single cluster of around induced increased expression of connective tissue growth factor
one hundred MR-modulating compounds, including dihydro- and hydroxyproline in cardiac fibroblasts, thus suggesting that
pyridines.27 Among them, 1f was identified as a selective sub- the MR could be a biological target for the treatment of fibrosis
micromolar MR antagonist (Table 1.2), but it was associated in the atrial myocardium.30
with a number of liabilities, such as low metabolic stability in The binding mode of DHP antagonists has been studied by
microsomes and significant interaction with L-type Ca2+ means of induced-fit-molecular docking against available MR-
channels.25 As previously observed, the R configuration at the LBD X-ray structures, such as MR-LBD complexed with
DHP core was preferred, and N-alkylation led to loss of corticosterone (PDB ID 2A3I),7 for derivatives 1b and 1e, or
potency. Other modifications that also decreased potency were with deoxycorticosterone (PDB ID 2ABI) to study R-1k.24,26,27
the dehydrogenation of the DHP nucleus to pyridine, the The helix 12 of the MR LBD was truncated, since the binding
change of the DHP ring by similar scaffolds as 1,4- pocket was too small to accommodate the branched ligands.
dihydropyrimidines, 1,4-dihydropyridazines, and 3,4-dihydro- These studies have identified key phamachophore points within
pyrimidin-2-ones, or the attachment of highly hydrophilic the 1,4-DHP derivatives, namely a hydrogen bond acceptor
groups to various positions of the DHP core.25 Several (e.g., donor DHP-NH), an aromatic moiety at the 4-position,
2631 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Table 1.3. IC50 of Naphthyridinamide Derivatives on Several Steroid Hormone Receptors

IC50 (nM)a
compd R1 R2 R3 MR GR AR PR
1n CN H H 100
S-1n CN H H 47 6900 2800 5400
S-1o CN H Me 26 5800 2400 4200
S-1p CONH2 H Me 1825 ≥10000 ≥10000 ≥10000
(58)40
a
Functional cell-based transactivation assay. Luciferase assay.

which resides in the known A-ring binding pocket of the steroid introduced at positions 7 and 8 (e.g., 1o).25 Interestingly, the
MR antagonist binding mode, and lipophilic moieties at 3- and/ replacement of the 3-cyano group by a primary amide led to a
or 5-positions (e.g., alkyl esters). Specifically, the NH group of potent MR antagonist with remarkable selectivity toward GR,
the 1,4-DHP ring (e.g., compounds R-1b and R-1e26 and R- AR, and PR (finerenone, BAY 94-8862, 1p).25 This compound
1k27) forms a hydrogen bond with H3 helix Asn770.23 The has higher selectivity than spironolactone and improved affinity
hydrophobic ester group fills the α-face pocket formed by for the MR than eplerenone. Compound 1p was explored on
hydrophobic residues Leu814, Leu827, Phe829, Met845, 65 different enzyme and ion channel assays without significant
Cys849, Met852, and Leu938 (e.g., compounds R-1b, R-1e, effects at 10 μM.25 Clinical studies with 1p suggested that, in
and R-1k). On the other hand, substituents at the opposite site, comparison with spironolactone, a lower dose may be at least as
a methyl and either a CN or COMe group, protrude toward the effective in reducing ventricular remodeling, with lower
β-face pocket (e.g., Ala773, Trp806, Ser810, and Leu 960), incidence of hyperkalemia and renal adverse events.34 More
either directly impinging on Leu960 in H12 helix or indirectly recently it was shown that it was able to protect rats from
by perturbing Trp806 in H5 helix (e.g., compounds R-1b, R-1e, cardiorenal injury.35 These findings provided impetus for
and R-1k). The 4-aryl groups occupy the A-ring pocket, and further clinical evaluation of 1p, which entered in phase II
depending on the DHP derivatives, they interact with Phe829 studies for the treatment of congestive heart failure and diabetic
(e.g., compounds R-1b and R-1e), Arg817, or Gln776 (e.g., nephropathy. The latter phase II trial focused on the effect of
compound R-1k). The formation of hydrogen bonds between 1p on albuminuria in patients with diabetic nephropathy
the DHP derivatives and Arg817 and Gln776 indicates that the receiving an angiotensin-converting enzyme inhibitor or an
4-aryl groups are equivalent to the steroid C3-carbonyl in the angiotensin receptor blocker. The data showed that admin-
A-ring moiety. It has also been shown that DHPs partially
istration of 1p led to an improvement in the urinary albumin-
overlap with the steroidal skeleton of MR antagonists.
creatinine ratio, with a dose-dependent reduction at day 90
Interestingly, the proposed DHP derivatives binding mode
ranging from 21% to 38% when compared to placebo in the
fails to overlap the entire steroid D-ring region, impeding the
dosage group of 7.5 to 20 mg/d compared with placebo.36−38
stabilizing contacts with the H11 helix, including Thr945. Thus,
it has been suggested that the incomplete occupancy and In the second phase II trial, 1p was studied in patients with
stabilization of the receptor-binding pocket, as well as the steric worsening heart failure, who also had diabetes mellitus and/or
clashes caused by the branched DHPs, explain the passive MR chronic kidney disease.39 These patients are at higher risk of
antagonism of these ligands.27 These binding modes have been developing hyperkalemia, so they are less likely to receive
supported by site-directed mutagenesis studies.25,27 The high steroidal MR antagonists. The overall result of these studies
selectivity has been linked to the fact that the MR is the only indicated that 1p reduces the levels of pro-B-type natriuretic
oxosteroid receptor having an alanine residue (Ala773) in the peptide (NT-proBNP), as shown by the decrease of over 30%
H3 helix and a serine residue (Ser810) in the H5 helix, while from baseline found in 38.8% and 34.2% of the patients in the
the AR, GR, and PR have glycine and methionine at their 10 → 20 mg and 15 → 20 mg 1p groups, respectively (initial
corresponding positions, respectively.31,32 For example, the dose → up-titrated dose), a similar extent to that of eplerenone.
DHP derivative R-1k is able to form contacts with Ala773 and Moreover, and similar to eplerenone, 1p showed a good safety
Ser810, while neither glycine nor methionine is able to make profile, with hyperkalemia (serum potassium concentrations
contacts in AR, PR, and GR, thereby explaining their high ≥5.6 mmol/L) only observed in 4.3% of the patients. This
selectivity toward the MR. study also indicated that 10 → 20 mg of 1p is the most suitable
The SAR was further extended with a series of heterobicyclic dosage. The promising results of these phase II studies have
analogues. Among them, 1,4-dihydro-1,6-naphthyridine deriv- allowed the clinical development program for 1p to be
atives, as 1n, can be considered as conformationally frozen expanded with phase III studies for chronic heart failure and
bioisosteres of 1,4-DHP esters (Table 1.3).5,33 In an effort to diabetic kidney disease, as recently announced by Bayer in
improve selectivity vs other NHRs, a methyl group was September 2015.
2632 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Docking studies of S-1p at the MR LBD X-ray structure Table 2.1. Pyrrole Derivatives as MR Antagonist (IC50 < 500
(PDB ID 2ABI9 devoid of helix 12) indicated a similar binding nM)
mode as the above-mentioned for other DHP derivatives,
forming hydrogen bonds with Asn770, Gln776, and Arg817.40
Moreover, it confirmed the key roles of Ala773 and Ser810 for
the high MR selectivity over the AR, PR, and GR. These
structural studies also found that the binding pocket of the MR
LBD in its agonistic conformation seems to be too small to
accommodate non-steroidal ligands, thereby suggesting that the
DHP-type MR antagonists act as bulky antagonists. This latter
docking model of MR LBD complexed with S-1p was validated
by carrying out point mutations within the binding pocket.
Strikingly, both A773G and S810M mutations led to a dramatic
decrease in the S-1p antagonistic potency. IC50 value increased
respectively by ∼24- and 88-fold for MRWT.40 These results
strongly corroborate that Ala773 and Ser810 favor the selective
binding of S-1p to the MR, while glycine and methionine at
these respective positions, as in the AR, PR, and GR, impair S-
1p binding.
Merck also claimed a number of 1,4-DHPs as MR
modulators. After the analysis of different substituents at
every position of the DHP ring, they discovered several
compounds with sub-micromolar binding affinity (e.g., 1q−1t,
Table 1.4).41 a
Gal4/LBD cell-based reporter assay.

Table 1.4. Binding Affinity of Selected Merck DHPs for the Table 2.2. IC50 Values of 1H-Pyrrole 3-Carboxamide MR
MR Inhibition

a
Binding affinity was determined using a competitive binding assay
with 3H-aldosterone and recombinant rhesus MR.

2. Five-Membered Nitrogen Heterocyclic Rings as
Central Scaffolds in MR Ligands. 2.1. Pyrrole Derivatives.
a
Exelixis developed a series of compounds with a common Gal4/LBD cell-based reporter assay. bMixture of atropisomers A and
structural pyrrole motif. One of them, CS-3150 (2k), entered in B. cThe corresponding 2f−2k atropisomers have an IC50 > 1000 nM.
phase III clinical trials in 2016.42 This work started from a series
of derivatives able to modulate 50% of the MR activity at MR antagonist action.44,45 The pharmacological profile of
concentrations below 500 nM (2a−2e, Table 2.1).43 These compound 2k was further investigated.42 In these studies 2k
compounds presented a 1H-pyrrole-3-carboxamide or a 1H- showed a good selectivity profile over other human steroid
pyrrole-2-carboxamide structural core with different substitu- hormone receptors (at least 1000-fold more selective for MR
ents attached. over GR, AR, and PR), which could result in reduced sex-
In March 2006, Exelixis and Daiichi Sankyo entered into a hormone-related side effects. Compound 2k also showed more
joint research agreement to develop modulators of the MR, potent MR antagonism and longer-lasting activity than the two
which led to two patents in 2010. These new 1H-pyrrole-3- currently marketed drugs, since it was able to inhibit the
carboxamide compounds showed atropisomerism (2f−2k, aldosterone-induced decrease in urinary Na+/K+ ratio in rats by
Table 2.2), and only one of the atropisomers exhibited high 56% at 20 h, whereas spironolactone inhibited the decrease at
2633 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

20 h by less than 20% and eplerenone at 8 h by around 8%, Table 2.3. MR Pyrazoline Antagonists
following oral administration to rats. Moreover, compound 2k
exhibits more potent antihypertensive and cardiorenal
protective effects in a Dahl salt-sensitive hypertensive rat
model than the two marketed drugs.46 Indeed, 3 mg/kg of 2k
inhibited the elevation in systolic blood pressure in DOCA/
salt-loading rats, whereas spironolactone and eplerenone did
not show significant effects at 30 mg/kg. The overall results
prompted the initiation of phase II clinical trials to treat
patients with hypertension and diabetic nephropathy. In March
2016 this compound started phase III clinical trials in essential
hypertension.
2.2. Pyrazoline Derivatives. Pfizer identified pyrazoline 2l
(Figure 2.1) as an acceptable MR antagonist during a high-

Figure 2.1. Pfizer pyrazoline derivative 2l.

throughput screening (HTS) campaign.47 Starting from this hit,
and in an effort to improve activity and solubility, they analyzed
substituents at the pyrazoline 1, 3, and 5 positions. Regarding
the aromatic moiety at N1, the cyano substituent was the most
appropriate replacement for the nitro group (Table 2.3), while
a small nonpolar substituent at R2 brought a 2-fold improve- a
Gal4/LBD cell-based reporter assay.
ment in potency (2m vs 2n and 2o, Table 2.3).47,48 As for the
aromatic ring at position 3, the introduction of a 4-carboxylate
Table 2.4. IC50 Values of Conformationally Restricted
group led to potent MR antagonists with reduced hERG
Pyrazoline Derivatives
channel inhibitory potency. At position 5, the R configuration
was the most favored (R-2m vs S-2m, Table 2.3), and the
replacement of the 4-fluorophenyl group by a cyclopentyl
moiety led to a slight improvement in potency (2m vs 2p, 2n vs
2q).47,48 Further modifications by addition of alkoxy groups
resulted also in potency enhancement for 2r−2t.47,48
A related series resulted from the conformational restriction
through cycling the phenyl ring at position 3 to the pyrazoline
scaffold. A six-membered ring (2u−2w, Table 2.4) was
preferred over the corresponding lower five-membered
homologue.47,49 As in the non-restricted series, the stereo-
chemistry at C3 was essential for potency, whereas that of C3a
was only of marginal importance. Compound PF-3882845
(3S,3aR-2w) displayed high affinity for the MR, selectivity over
other steroid receptors (PR IC50 = 416 nM, AR IC50 = 8960
nM, GR and ER IC50 > 10000 nM) as well as a good
pharmacokinetic profile.47 Moreover, 3S,3aR-2w reduced blood
pressure and protected the kidneys in a preclinical model of
hypertension induced in Dahl salt-sensitive rats. 3S,3aR-2w
entered clinical trials for diabetic nephropathy,47 but its
development was discontinued in 2012.
Molecular docking studies has been carried out to get a
Gal4/LBD cell-based reporter assay.
insights into the binding pocket of 2w.47 Unlike the DHP
compounds, pyrazoline derivatives do not make the stabilizing
contact to Asn770 residue (H3 helix). This binding feature by
2634 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

itself could explain their MR antagonism, because it has Table 2.6. MR Binding Affinity of Imidazole Derivatives (Ki
previously been suggested that MR steroidal activation, in Values)
addition to the C3-ketone group, requires ligands able to
engage in hydrogen bonding to Asn770 (H3 helix) and Thr945
(H11 helix).23,47 Similarly to the binding mode of some DHP
derivatives (e.g., S-1p), the cyano phenyl group of 2w sits in the
A-ring pocket forming hydrogen bonds, with Gln776 (H3
helix) and Arg817 (H5 helix), thus mimicking the A-ring C3-
carbonyl group of steroidal ligands (e.g., corticosterone).
In spite of the good properties of 3S,3aR-2w, there was still
room for improvement. To this end, Pfizer focused again on compd R1 R2 R3 MR Ki (nM)a
non-conformationally restricted pyrazoline analogues, in 2ac H Me H 134.4
particular R-2r, because of its increased selectivity over PR 2ad H 3,5-di-Cl-Ph-CONH H 161.7
and its improved solubility.50 The MR potency and selectivity 2ae Me H H 285
rose upon the replacement of the 1-(3-chlorophenyl) ring by a
Binding affinity was determined using a competitive binding assay
the corresponding 3-methyl-substituted analogue, and even with 3H-aldosterone and recombinant rhesus MR.
more upon incorporation of a nitrogen in the benzoic acid
moiety, resulting in compound 2x, with a selectivity over PR subcutaneous dose but showed lower activity than spirono-
>500-fold (Table 2.5).50 The incorporation of a nitrogen within lactone at 10 mg/kg.53
2.4. Oxazolidinedione Derivatives. Merck Research Labo-
Table 2.5. Activity of Pyrazoline Derivatives in the MR and ratories recently described the discovery of a new class of MR
the PR antagonists based on the oxazolidine-2,4-dione scaffold. Starting
from a HTS of an in-house collection, compound 2af was
selected as a modest MR ligand for a thorough optimization
strategy (Table 2.7).54,55 First, the importance of the absolute

Table 2.7. MR Ligands with an Oxazolidinedione Central
Scaffold

IC50 (nM)a
compd Y R MR PR solubilityb (μM)
2x CH OH 4.5 2530 312
2y N OH 7.6 1590 324
2z CH NH2 2.7 494 <25
2aa CH NHSO2Me 2.8 2480 239
2ab N NHSO2Me 4.1 831 39
a
Gal4/LBD cell-based reporter assay. bKinetic solubility determined as
previously described.51

the aromatic ring displaying the nitrile (2y) did not change
significantly the MR activity or solubility.50 The replacement of
the carboxylic acid by amide derivatives did not improve the
MR potency or the selectivity over the PR and decreased
kinetic solubility (2x vs 2z).50 In contrast, acylsulfonamide
analogues (2aa, 2ab) increased the MR potency while
maintaining low PR activity.50 Thus, compound 2aa displayed
>800-fold selectivity for the MR over the PR. However, the
high in vitro liver microsomal intrinsic clearance of 2aa (Clint =
175 μL/min/mg) motivated the authors to focus additional
efforts on 2x (Clint < 14 μL/min/mg). Oral administration of
2x in rats significantly increased the urinary Na+/K+ ratio at the
doses of 10 and 30 mg/kg. The effect of 2x was dose-
dependent. This compound behaved as a MR antagonist, with a
good selectivity over other NHRs and improved solubility in Values obtained using a commercially available protein−protein
comparison with 2w, and showed in vivo efficacy. Therefore, 2x interaction cell-based assay.56
was selected for further preclinical profiling.50
2.3. Imidazole Derivatives. In 2008, Merck patented several configuration of 2af was recognized, as its enantiomer was
imidazole derivatives with antagonist MR activity (some inactive (IC50 > 40 μM), as well as the positive contribution of
representative examples, 2ac−2ae, are collected in Table a methyl group as R1 substituent (2ag−2ai).54 According to
2.6).52,53 Compound 2ae was selected to test a protocol for molecular modeling studies, this methyl plays a key role in
determining the anti-mineralocorticoid activity of compounds favoring the conformation which is preferred for receptor
dosed in rats. This compound was active at a 30 mg/kg binding. The incorporation of fluoro or chloro substituents on
2635 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

the R1 phenyl ring (2ai), as well as the introduction of a ring ion channels (IC50 > 6 μm), and CYPs (IC50 > 19 μm) as well
fused to the phenyl group (2aj) maintained the affinity.54 The as a reasonable rat PK profile.57,59 As previously observed, the
benzyl group at position 5 of the oxazolidinedione ring was also incorporation of a 3,5-dimethoxyphenyl substituent at position
an important element, as its replacement by H led to an R increased potency (2an vs 2am).
inactive compound. The optimization of the group attached to Authors also envisaged the benzimidazole as a replacement of
the amide bond revealed that certain substituents on the benzyl the amide moiety of compounds like 2ag. These benzimida-
moiety (R2, R3, R4) increased the affinity, as in 2ag and 2ah. In zole-based oxazolidine derivatives combined similar MR
contrast, the incorporation of monocyclic or fused bicyclic aryl potency with improved rat liver microsomal activity (Table
or heteroaryl moieties generally led to a decreased MR activity. 2.9).60 The SAR studies with respect to R1 and R2 showed that
Interestingly, an increase in activity was observed for the
cyclohexyl analogue 2ak, the most potent compound within Table 2.9. MR Activity of Benzimidazole-Based Oxazolidine
this series.54 Finally, attempts to change the oxazolidinedione Compounds
core led to inactive analogues. Theoretical studies suggested
that this scaffold was essential to place the pharmacophore
groups in the right pocket regions. Compound 2ai showed an
acceptable selectivity profile against several nuclear receptors,
including GR, AR, ERα, ERβ, and PRβ (EC50 agonist mode
assay values >20 μM and IC50 antagonist mode assay >8 μM).54
Next, aiming at improving physicochemical and ADME
(absorption, distribution, metabolism, and excretion) properties
and safety profiles, the cyclization of the amide moiety was
explored (2al−2aq, Table 2.8) as a way of avoiding amide

Table 2.8. IC50 of Oxazolidinedione-Derived MR Ligands
with Heteroaromatic Substituents at Position 5

a
Commercially available protein−protein interaction cell-based
assay.56 bPercentage of compound (1 μM) remaining at 0.5 h and
incubation in human (hLM) and rat (rLM) liver microsomes.
a
Commercially available protein−protein interaction cell-based
assay.56 small substituents such as halides (2ar, 2ax, 2ay) or
trifluoromethyl (2az) led to modest MR activity, whereas the
hydrolysis, one of the primary metabolic pathways of these incorporation of heteroaryls or heterocycles at R2 led to several
compounds.57−59 The authors analyzed different rings, among compounds with improved IC50 values (2as−2aw).60 These
them imidazole, oxazole, triazole, oxadiazole, and benzimida- derivatives had acceptable human microsomal stability (>50%
zole. Imidazole and 1,3,4-oxadiazole derivatives, 2an and 2ap, of parent compound remaining after 30 min of incubation).
showed improved potency and lipophilic ligand efficiency Moreover, in a natriuresis rat model the effect of compound
(LLE) compared with the 1,2,4-triazole, 2ao. The inclusion of a 2au at 100 mg/kg was comparable to that of spironolactone at
cyclopropyl ring at the benzylic position, as in 2aq, led to an 30 or 100 mg/kg. Authors noted that previous monocyclic
enhancement in human metabolic stability. Both 2ap and 2aq heteroaryls (Table 2.8) exhibited much weaker efficacy in the
showed significant selectivity over other NRs (IC50 > 5 μm), same model.
2636 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

3. Aryl Sulfonamide Derivatives as MR Antagonists. permeability (RRCK, Papp = 10−6 cm/s, 15.4) and metabolic
Pfizer identified an aryl sulfonamide based MR antagonist, 3a, stability (CLint,app = 9.6 μM/min/million cells).
through a HTS of its in-house collection (Figure 3.1).61 The sulfonamide moiety is also within a series of biaryl amide
derivatives, developed by Dainippon Sumitomo Pharma, which
also provided molecules able to bind to the MR.63 They
explored a wide variety of substituents at the aromatic rings by
preparing more than five hundred compounds. The methoxy
and sulfamide substituents were always among those with the
higher activity (Table 3.2). Additionally, different R1 and R2

Figure 3.1. Sulfonamide-based MR antagonist identified through HTS. Table 3.2. MR IC50 Values for Representative Sulfonamide-
Substituted Biaryl Amide Derivatives
Subsequent studies revealed that the replacement of the
thiophene ring by a phenyl ring led to a modest improvement
in MR binding affinity, as in derivative 3b (Table 3.1).61

Table 3.1. MR Binding (IC50) and Physicochemical
Properties of Aryl Sulfonamide Derivatives

a
Competitive binding assays using [3H]aldosterone. bLipE = Pic50 −
a
elogD. Competitive binding assays using [3H]aldosterone in a rat renal
soluble fraction in the presence of RU-486 to avoid binding to the
However, both compounds had a low lipophilic efficiency glucocorticoid receptor.
(LipE). Consequently, an optimization process was carried out
to improve this parameter and the metabolic stability. groups could be incorporated while keeping high affinity (e.g.,
Modifications of the R1 substituent led to compound 3c that 3f−3k), whereas substituents at other positions rendered less
showed the best balance of LipE and metabolic stability.61 To active compounds (Table 3.2).63
improve affinity over 3c a sulfonamide library was prepared, 4. Pyridyl Ureas as MR Antagonists. Boehringer
Ingelheim International GMBH studied a series of compounds
from which the replacement of the isoxazole ring with
involving a pyridyl urea linked to a phenyl moiety by a pyrazole,
substituted phenyls afforded derivatives with improved proper- 4a (Figure 4.1), or an ethylene spacer, 4b−4g (Table 4.1).64 In
ties, like 3d and 3e.61 Compound 3e was considered a general, the best results were obtained with the ethylene linker,
promising lead for optimization because it was selective against particularly in the functional assay (Table 4.1). A variety of
PR (>48-fold selectivity), AR (no antagonist activity up to 10 substituents are permitted on the ethylene moiety, at R1, such
μM), and GR (>11-fold selectivity) and exhibited good passive as aliphatic chains or aromatic moieties (4c, 4d, Table 4.1). The
2637 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

incorporation of F at R3, as in 4e, improved binding affinity and
led to derivatives with binding IC50 values below 30 nM,
whereas substitution by CH3, CF3, or OCH3 led to values over
100 nM, as in compound 4f.
5. Indole- and Indazole-Derived MR Ligands. Eli Lilly
and Company, in a search for non-steroidal human MR
antagonists, and on the basis of screening, identified a series of
indole derivatives with interesting properties. They reported
two series, one with a 3,3-bisaryloxoindol skeleton, and the
other with a quaternary carbon serving as the scaffold
Figure 4.1. Example of a [(pyrazol-3-yl)pyridin-2-yl]urea MR
supporting an indole ring and at least another aromatic group.
antagonist. 5.1. 3,3-Bisaryloxoindole Derivatives. SAR studies on the
oxoindole derivative 5a, a human MR (hMR) ligand identified
Table 4.1. IC50 Values of MR Binding and Functional Assays through screening (Table 5.1),65 showed the importance of the
of Pyridyl Ureas phenol substituents, in particular of hydroxy groups, as their
replacement with H or OMe, led to inactive derivatives. An
increase in potency and selectivity was observed when the
phenyl ring was directly attached to the nitrogen atom of the
oxoindole core (5b), and particularly when a meta-substituent
was present, 5c and 5d.65 Unsymmetrical phenol derivatives,
like 5e−5g, showed good selectivity for the MR compared to
IC50 (nM) other steroid receptors (GR, PR, AR, and ER).65 The authors
MR MR suggested that the presence of a hydroxy group at R4 forces a
compd X Y R1 R2 R3 bindinga functionalb conformation that allowed the discrimination between the
4b N CH H Me H 7.1 19 binding pockets of MR and GR. The isolation of the 5g
4c N CH Ph H H 13 44 enantiomers showed that the (−)-isomer was more potent and
4d N CH Me Me H 11 43 selective than the (+)-isomer.
4e N CH H Me F 4.7 31 5.2. Indol-7-yl-methanesulfonamide Derivatives. Bell et al.
4f N CH H H Me 480 2800 explored the use of indole-derived compounds as modulators of
4g CH N H OMe H 25 97 steroid hormone nuclear receptors.66 In particular, they focused
a
MR competitive molecular binding assay based on the binding and on the MR and the GR. It is worth noting that the great
displacement of a TAMRA-labeled dexamethasone probe with majority of the compounds reported interact with both the MR
fluorescence polarization (FP) detection. bCommercially available and the GR with Ki values lower than 500 nM (Table 5.2). In
Gal4/LBD cell-based reporter assay (GeneBLAzer UAS-bla HEK 293 general, these compounds have two substituents on the indole
cell line).
ring at positions 3 and 7, the latter quite frequently a methane
sulfonamide moiety. A thorough exploration was carried out at
the indole position 3: through this position the indole ring was

Table 5.1. hMR Binding of Bisaryloxoindole Derivatives

Ki (nM)
compd n R1 R2 R3 R4 hMRa hGR hPR hAR hERα hERβ
5a 1 H Me Me H 65 − − − − −
5b 0 H Me Me H 27 147 44%b 41%b 733 >1100
5c 0 Me Me Me H 7 84 138 306 183 844
5d 0 OMe Me Me H 0.6 51 715 402 242 930
5e 0 OMe H H OH 3 793c 678 19%b >1100 >1100
5f 0 OMe H Me OH 1 693c 395 1105 >1100 >1100
5g 0 Me H Me OH 2 334 245 37% 579 >1100
5g(−) 0 Me H Me OH 1 582 33% 16%b 359 >1100
5g(+) 0 Me H Me OH 40 686c 49% 20% 519 >1100

a
Competitive binding assay using [3H]aldosterone bPercentage of inhibition at 1 μM antagonist concentration. cOne determination.

2638 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Table 5.2. Indol-7-ylmethanesulfonamide Derivatives with Ki Table 5.3. MR Antagonist Activity of Indazole Derivatives
Equal to or Lower than 500 nM for the MRa

compd R1 R2 R3 R4 R5 MR IP (nM)a,b
5r H Et Me Br Me 7
5s H Et Et Br Me 3
5t H Et Et CF3 Me 4
5u F Et Et CF3 Me 9
5v H CH2CHF2 Et CF3 Me 15
5w H Et CHF2 CF3 Me 11
5x H Et CHF2 CF3 Et 4
5y F Et CHF2 CF3 Et 11
a
Inflection point of the nonlinear regression curve. The IP value is
equal to the IC50 value when the slope is 1, the minimum is 0, and the
maximum is 100. bCommercially available protein−protein interaction
cell-based assay.56

Table 5.4. PK Profile in Rats and Metabolic Stability for
a
Ki values were calculated with a competitive binding assay using Indazole Derivatives
radioligands.66,67. stability, t1/2 (min)
CL t1/2 human liver human
attached to a tetrasubstituted carbon, which, in general, bear compd (mL/min/kg) (h) microsome hepatocyte
another aromatic ring and two aliphatic chains. As for the 5r 18 3.6 48 69
aromatic substituent, a wide variety of mono- or bicyclic 5t 24 5.3 72 >90
aromatic and heterocyclic moieties have been explored. Among 5w 3.8 9.9 62 >90
them, phenyl, thiophene, furan, benzofuran, indole, benzothio-
phene, benzodioxin, benzodioxole, benzimidazole, benzothia-
zole, benzooxazole, indazole, and biphenyl led to affinity below interesting moiety in the search of non-steroidal MR
500 nM (e.g., compounds 5h, 5k−5m, Table 5.2).66 These antagonists whose use has been explored by several
aromatic moieties supported in some cases an extra substituent, pharmaceutical companies. In 2006, Novartis patented a series
such as methyl, chlorine or fluorine (5i, 5j, 5o−5q).66 of 333 derivatives with a benzoxazin-3-one central core, bearing
Regarding the other two substituents in derivatives with a great variety of large substituents attached either directly or
significant Ki, both groups could be equal or different, and through a linker to position 6 (R2), including aromatic and
generally they were aliphatic groups, such as methyl (5n−5q), heteroaromatic rings (Table 6.1). Positions 5, 7, and 8 were less
ethyl (5h−5m), propyl, cyclopropyl (5n−5q), or cyclobutyl, or explored and had smaller substituents, such as methyl or
both substituents were within a five- or six-membered ring.66,67 fluorine. Several of these derivatives were able to bind to the
From the series of compounds with a Ki < 500 nM, the SAR MR (Table 6.1, compounds 6a−6c).69 In 2016, Vitae
studies showed the favorable effect of a proton donor at pharmaceuticals performed a SAR study with derivatives having
position 7 of the indole ring, particularly a methane variable substituents at position 6, finding several compounds
sulfonamide moiety, and the best combination for the dialkyl with an acceptable MR affinity, derivatives 6d and 6e.70
substituents was methyl/cyclopropyl (5n−5q Table 5.2). Toru Iijima et al., from Tanabe Seiyaku Co., focused on
Derivative 5p was further studied, showing that the S- substituents at positions 2, 4, and 7 of the 1,4-benzoxazin-3-one
enantiomer behaved as a potent, selective, and orally efficacious scaffold (Figure 6.1, I). Several derivatives were reported as
antagonist of the MR.67 Furthermore, in a rat model of having MR Ki values lower or equal to 500 nM, and in general,
hypertension, S-5p was more potent than the marketed drug they had two methyl groups at position 2 and either NHSO2Me
eplerenone and showed a better in vitro selectivity profile than or NH2 at position 7.71 More variety could be found at position
spironolactone. 4, with aromatic or heteroaromatic rings, as 4-fluorophenyl, 4-
5.3. Indazole Derivatives. Merck Sharp & Dohme Corp. fluoro-3-methylphenyl, 3,5-dichloropyridin-2-yl, benzyl, and so
described a series of indazole derivatives which display MR forth.
antagonist activity. Although the diastereoisomers and The benzoxazin-3-one ring is also within more complex
enantiomers were isolated, their stereochemistry was not structures, having monocyclic aromatic rings or fused-hetero-
disclosed within the patent. In Table 5.3, representative cycles as central scaffold (Figure 6.1, II). These compounds,
examples 5r−5y are collected.68 Compounds 5r, 5t, and 5w described in 2009, showed inhibition rates up to 70% at 10
have good metabolic stability in liver microsomes and μM.72 It was observed that the central scaffold A was tolerant to
hepatocytes as well as good PK profiles in rats (Table 5.4). modification, while keeping significant MR binding activity.
6. Benzoxazinones-Derived MR Ligands. 6.1. 1,4- Thus, Takeda pharmaceuticals studied different skeletons as
Benzoxazin-3-ones. The 1,4-benzoxazin-3-one bicycle is an replacement of this central scaffold. Starting from a HTS hit
2639 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Table 6.1. Binding Data of a Series of 1,4-Benzoxazin-3-ones Table 6.2. MR IC50 Values of 1,4-Benzoxazin-3-one-
Derivatives Containing Triazolothidiazine Derivatives

compd R1 R2 MR IC50 (nM)a
6f H H 510
6g F H 310
6h H F 270
a
Competitive binding assay using [3H]-aldosterone.

was found that both compounds have similar binding modes.
The 3D structure showed a small space around the phenyl
group; thereby, derivatives 6g and 6h were prepared.8
Compound 6h showed improved affinity and better selectivity
over other steroid hormone receptors than 6f.
The poor PK profile of 6h (metabolic clearance in rat
microsomes 60 μL/min/mg) led to the investigation of
alternative scaffolds without metabolically labile groups.8 The
replacement of the triazolothiadiazine ring by thiazole or
imidazole led to a decrease in the activity. In contrast,
derivatives 6i−6m with a pyrazole scaffold showed interesting
results (Table 6.3).8 The X-ray structure of the triazolothiadia-
zine derivative 6f was useful in the lead optimization of this
pyrazole series, in which a trifluoromethyl group was attached
to the 3-position of the pyrazole ring (as in 6i−6m) to fill the
a
space of the triazolothiadiazine ring (as in 6f).8 Subsequent
Gal4/LBD cell-based functional assay in HEK293 cells. bCompetitive optimization of the substituents on the benzene and
binding assay using 3H-cortisol. benzoxazine rings showed that the introduction of a methyl
group as R1 substituent (compound 6j) considerably enhanced
binding affinity.8 Further increases in affinity were achieved by
adding fluorine at R2, and chlorine or methyl at R3 (compounds
6k−6m). Compound 6k showed a good PK profile in SD rats
[CL = 1328 mL/h/kg, Vdss = 4626 mL/kg], as well as the best
balance of potency and selectivity (binding IC50 for AR, PR,
and GR was 2500 nM or higher), and was selected for in vivo
evaluation.8 These studies showed that 6k behaved as an MR
antagonist with blood-pressure-lowering effect similar to that of
spironolactone.8
Figure 6.1. General formulas of 1,4-benzoxazine-containing deriva- Taken together, the SAR studies on benzoxazin-3-one
tives. derivatives identified three main key pharmacophores, namely
a benzoxazin-3-one moiety, a 4-fluorobenzene ring, and a
and guided by docking studies, they identified compound 6f, central scaffold linking these two aromatic rings at adjacent
with a triazolothiadiazine skeleton as the central scaffold (Table positions, which can be exploited to develop more potent and
6.2).72 Even more, they solved the X-ray structure of the selective MR antagonists.8,73 Accordingly, a novel benzoxazin-3-
complex between 6f and the MRC808S/S810L-LBD (1.35 Å, PDB one derivative, having a dihydrofuran-2-one moiety as the
ID 3VHV)the first X-ray structure of a non-steroidal central scaffold, was selected as lead compound (Table 6.4).73
compound bound to the MR (Figure 6.2).8 This structure An X-ray co-crystal structure of the MR LBD/compound 6n
revealed the binding mode of the benzoxazin-3-one ring, in complex (2.05 Å, PDB ID 3WFF73) revealed the binding mode
which the NH group and the carbonyl oxygen of this moiety of dihydrofuran-2-one derivatives and guided the lead
form hydrogen bonds to Asn770. Also, the nitrogen atoms of optimization of the new benzoxazin-3-one-based compounds
the triazole scaffold establish hydrogen bonds to Gln776 and (Figure 6.3A). As expected, compound 6n binds to the MR-
through a water molecule to Arg817. The aryl group at the 2- LBD in a similar way as compound 6f. The NH group and the
position of the triazolothiadiazine ring partially filled the α-face carbonyl oxygen of the benzoxazin-3-one moiety forms
pocket providing the bases for further chemical optimization.73 hydrogen bonds to Asn770, and its carbonyl oxygen established
After superimposing the crystal structures of compound 6d and a new hydrogen bond to Thr945. The carbonyl oxygen in the
spironolactone bound to the MR-LBD binding-site cavity, it dihydrofuran-2-one scaffold establishes hydrogen bonds to
2640 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Figure 6.2. (A) Close-up view of the X-ray structure of the MRC808S/S810L-LBD double mutant bound to compound 6f showing its binding mode.
(B) Superimposition of the X-ray structures of compound 6f (yellow) and spironolactone (orange) bound to the MRC808S/S810L-LBD (PDB IDs
3VHV and 3VHU, respectively). The hydrogen bonds and water molecules are depicted as yellow dashed lines and red spheres, respectively.

Table 6.3. MR Binding IC50 of 1,4-Benzoxazin-3-one- Table 6.4. IC50 Binding to MR, PR, and GR of
Containing Pyrazole Derivatives Dihydrofuran-2-one and Dihydropyrrol-2-one Derivatives
Containing a 1,4-Benzoxazin-3-one Ring

compd R1 R2 R3 MR IC50 (nM)a
IC50 (nM)a
6i H F H 260
6j Me H H 80 compd R1 R2 R3 X MR PR GR
6k Me F H 41 6n H F H O 660 4600 >10000
6l Me F Cl 12 6o Me H H O 120 740 3800
6m Me F Me 21 6p Me H H N-Et 33 770 1600
a
Competitive binding assay using [3H]-aldosterone. 6q Me H H N-c-Prb 68 400 2200
6r Me H H NH 94 5600 9100
6s Me H Cl NH 23 1600 1100
Arg817 and Gln776 through a water molecule. It was also
6t Me H Me NH 43 >10000 4900
observed the existence of three lipophilic spaces that could be a
filled with adequate groups at X, R1, and R2.73 At dihydrofuran Competitive binding assay using [3H]-aldosterone, [3H]-progester-
position 5, a methyl substituent (6o) was optimal, whereas a one, or [3H]-dexamethasone to test binding to MR, PR, and GR,
bigger ethyl group led to a decrease in binding activity.73 The respectively. IC50 binding to AR was >10 000 nM in all cases. bc-Pr =
cyclopropyl.
binding mode of compound 6o is similar to that of compound
6n, as observed in the solution of the crystal structure of the
MR-LBD/compound 6o S-enantiomer complex (1.40 Å, PDB study the R3 substituent. Compounds 6s and 6t showed higher
ID 3WFG73) (Figure 6.3B). The X-ray co-structure of MR activity and were equipotent to spironolactone.73 More-
compound 6o in the MR LBD suggested that the S-enantiomer over, the methyl derivative 6t has decreased PR activity
should be more potent than its R counterpart, and that a compared with 6r (Table 6.4).
lipophilic group should be adequate at position 1 (Table 6.4).73 In functional assays, compound 6t and most of the
Therefore, the central scaffold was replaced by a dihydropyrrol- dihydropyrrol-2-one derivatives showed also moderate partial
2-one ring. As indicated in Table 6.4, ethyl and cyclopropyl agonistic activity at high concentrations (20−30% at 10 μM),
derivatives 6p and 6q showed increased binding activity.73 whereas the values obtained for pyrazole analogues, such as 6k,
Unexpectedly, the unsubstituted NH derivative 6r exhibited were low. The X-ray structure of the MR LBD bound to 6o
high binding activity, which could be explained by the increased (PDB ID 3WFG),73 close analogue of 6t, suggested a role of
electron density of the carbonyl group in the dihydropyrrol-2- the central ring carbonyl group in a water-mediated hydrogen
one scaffold compared to the dihydrofuran-2-one framework, bonding network. Since this network was considered not to be
reinforcing the water-mediated hydrogen bonds with Arg817 present in 6k, it was assumed that it was important for the
and/or Gln776.73 Regarding the high selectivity of 6r over the partial agonist effect. As the clinical efficacy and safety of partial
AR, PR, and GR compared to 6p and 6q (Table 6.4), its N- agonists remain unclear, other azole rings, with no possibility to
unsubstituted dihydropyrrol-2-one ring was shown to be a key form these water-mediated hydrogen bonds, were selected, with
scaffold for such a property compared to the dihydrofuran-2- the pyrazole scaffold providing the best MR activities (6u−6z,
one moiety. Further efforts were focused on compound 6r to Table 6.5).74,75 However, derivatives 6v−6x also showed high
2641 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Figure 6.3. Close-up views of the MRC808S/S810L-LBD double mutant bound to benzoxazin-3-one-based compounds: (A) 6n (magenta), (B) 6o (S-
enantiomer, pink), and (C) 6z (blue) (PDB IDs 3WFF, 3WFG, and 4PF3, respectively). The hydrogen bonds and water molecules are depicted as
yellow dashed lines and red spheres, respectively.

Table 6.5. MR Activity of 1,4-Benzoxazin-3-one-Containing contribution of these fluorine atoms to the binding is
Pyrazole Derivatives hydrophobic.
Pfizer has also explored compounds with a morpholine
central ring (Table 6.6). They observed that the incorporation

Table 6.6. MR IC50 of 1,4-Benzoxazin-3-one-Containing
Morpholine Derivatives

IC50 (nM)
compd R MR bindinga MR activityb
6u n-Pr 22 45 (0%)
6v CH2CH2CF3 8.4 33 (6%)
6w CH2CF2CH3 10 18 (4%)
6x CF2CH2CH3 5.8 27 (11%)
compd R1 R2 X Y MR IC50 (nM)a
6y 3-Py 36 36 (−4%)
6z CF2CH2OH 51 71 (1%) 6aa H H CH CH 24
a 3 b 6ab H H N CH 44.4
Competitive binding assay using [ H]-aldosterone Cell-based
6ac F H 33.4
reporter gene assay. Antagonist activity and, in parentheses, agonist
activity at 10 μM concentration. 6ad H F 55
6ae F H CH N 53.9
a
Gal4/LBD cell-based reporter gene assay.
metabolic clearance in rat microsomes (>100 μL/mg/min),
which was attributed to their high lipophilicity (logD > 3).
Design of less lipophilic derivatives allowed the identification of
several potent compounds that have significantly reduced at morpholine N4 of benzoxazin-3-one, 6aa, or pyridoxazinone
partial agonistic activities and high selectivity over other steroid moieties, 6ab−6ae, led to derivatives with IC50 values below
receptors, like 6y and 6z (binding IC50 AR and PR > 10 000 100 nM, nevertheless the former provide the most active
nM, GR > 1700 nM).75 Compound 6z showed an acceptable derivative.76 There was a decrease in affinity caused either by
metabolic clearance (42 μL/mg/min), and it was able to lower the removal of the aromatic ring at position 5 (IC50 = 3050
the blood pressure in DOCA-salt hypertensive rats, without nM) or the methyl at position 2 (IC50 = 1970 nM) in derivative
antiandrogenic effect. The crystal structure of the complex 6ab. It was also observed that the incorporation of a fluorine
between 6z and the MR LBD (1.10 Å, PDB ID 4PF3)75 atom in the ortho or meta-position of the phenyl ring keeps the
showed that it binds to the steroid binding pocket of the MR. affinity (6ac, 6ad), whereas it is detrimental in the para-
As expected, the binding mode of compound 6z is similar to position.76
that of compounds 6n (Figure 6.3C). The NH group and the 6.2. 1,3-Benzoxazin-2-ones. 1,3-Benzoxazin-2-one and -2-
carbonyl oxygen of the benzoxazin-3-one moiety form thione derivatives also provided compounds able to interact
hydrogen bonds to Asn770 and Thr945, and the 4- with the MR, which are collected in two Knobbe Martens
fluorobenzene ring occupies the α-face hydrophobic pocket. Olson & Bear LLP patents77,78 and one from Dainippon
The ligand side chain at the 1-position of the pyrazole ring, the Sumitomo Pharma Co (6af, SM-368229, Figure 6.4).79 In
2,2-difluoropropyl-3-hydroxy group, points out toward Arg817 particular, a study on the pharmacological profile of 6af
and Gln776. Its hydroxyl group directly forms a hydrogen bond indicated that this compound was able to increase urinary Na+/
to Gln776. The two fluorine atoms do not form any specific K+ ratio in adrenalectomized rats treated with deoxycortico-
hydrogen bonding interactions suggesting that the major sterone acetate. Even at doses of 300 mg/kg, only very weak
2642 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

increased for the diacetylated analogue 7b, however further
increase of the steric hindrance at R1 and R2 substituents (Et,
iPr, or n-Pr) tended to decrease activity.81 The influence of the
ring size was also investigated from the 11- to 14-membered
lactone ring; the 11-membered ring derivative 7c showed the
best inhibitory activity.81
8. Fused Heterotricyclic Derivatives as MR Ligands. Eli
Figure 6.4. 1,3-Benzoxazin-2-ona derivative from Dainippon Sumito- Lilly and Company described a series of tricyclic steroid
mo Pharma Co. hormone receptor modulators with the capacity to bind to the
MR and the GR with Ki ≤ 500 nM. The general structures are
antiandrogenic effects were observed in methyltestosterone- shown in Figure 8.1. For derivatives of general formula III, the
treated male rats.79 tricyclic structure of the reported compounds with Ki lower
Mitsubishi Tanabe has investigated related compounds than 500 nM corresponds mainly to a thioxanthene scaffold (X
derived from 2H-1,3-benzoxazine (Y = N, 6ag, 6ah) and 2H- = S), but there are also examples in which X is a methylene
chromene (Y = C, 6ai, 6aj), reporting several compounds that group or an oxygen atom. R1 is usually hydrogen or methyl, and
showed sub-micromolar MR dissociation constants (Table Ar is an aromatic group such as phenyl, benzimidazol-2-one,
6.7).80 Most of them have a phenyl ring at position 4 of the benzoxazol-2-one, or benzothiazol-2-one.82 A tricyclic structure
with a seven-membered ring has also been explored, structure
Table 6.7. Examples of 2H-1,3-Benzoxazine and 2H- IV (Figure 8.1), and the authors reported almost 200
Chromene Derivatives with MR Ki Values below 500 nMa compounds with significant Ki values. In particular, within
these compounds the most recurrent were dihydrobenzo[a,d]-
[7]annulene derivatives (X = Y= C and two phenyl moieties
flanking the seven membered ring). However, there are also
several examples where X = S, SO, SO2, or O (Y = C), or
alternatively Y could be an oxygen atom, and X could be a
carbon. As for R8, it is mainly a hydrogen atom.83 More variety
of substituents is observed in the C ring, which might be a
phenyl, benzimidazol-2-one, benzimidazole, indolyl-2-one,
benzoxazol-2-one, or benzothiazol-2-one. Subsequent patents
compd Y R1 R2 R3 R4 focused on a tricyclic scaffold with a central seven-membered
6ag N Cl H H − ring of general formula V (Figure 8.1 and Table 8.1). A 2005
6ah N F H Me − patent described a series of derivatives with either a tricyclic
6ai C F H H Me dihydrodibenz[b,e]oxepine (X = O) or dihydrodibenz[a,d][7]-
6aj C Cl Me H H annulene (X = CH2) showing good Ki values.84 For the active
a
Competitive binding assay using [3H]-aldosterone. compounds reported, R1 and R2 are independently selected
from hydrogen or fluorine, and at the R3 position a variety of
heterocycles are suitable (Figure 8.1, formula V, Table 8.1).85,86
scaffold, although there is an example with a benzothiophene Within this family, compound 8a showed good affinity for the
ring. The most frequent substituents at position 2 are methyl MR and selectivity over the AR, BR, and PR, and behaved as a
groups, whereas either methyl or hydrogen are suitable at potent and selective antagonist of the hMR (IC50= 21 nM in
position 5. In the chromene (Y = C) scaffold, H, CN, and Br functional assays).86 In in vivo models, 8a displayed potent
are adequate as R4 substituents for interacting with the MR (Ki reno-protective activity, antihypertensive effects, and a reduced
< 500 nM). probability of producing hyperkalemia.
7. Macrolide MR Antagonists. In an screening program to In 2009, Eli Lilly and Company focused on a series of
search for non-steroidal MR antagonist, compound 7a, dihydrodibenz[b,e]oxepines based on the previously reported
methyllasiodiplodin, was found and reported as the first tricyclic steroid hormone receptor modulators (Figure 8.1, IV
macrolide MR antagonist (Table 7.1).81 The antagonist effect and V).83,84 Representative compounds with Ki ≤ 10 nM are
collected in Table 8.1. At R3 position several heterocycles led to
Table 7.1. Inhibitory Activity of O-methyllasiodiplodin compounds with significant activity, where R4 was O, N-CN, or
Analogues N-CONH2. Interestingly, these derivatives have at least one
fluorine atom at the C3 position, and the authors analyzed
systematically the presence of another fluorine either at R1 or
R 2 . In general, for each R 3 and R 4 substituent, the
corresponding 3-fluoro (R1 = H, R2 = H), 3,7-difluoro (R1 =
H, R2 = F), and 3,8-difluoro (R1 = F, R2 = H) derivatives have
been prepared and evaluated (i.e., 8a−c or 8d−f).85,86
compd R1 R2 R3 n IC50 (nM)a The authors also carried out an exhaustive modification of
7a H H Me 5 8930 the configuration of the chiral centers of R3 substituents, and
7b Ac Ac Me 5 2780 for the reported examples, Ki values were below 10 nM
7c Ac Ac H 4 580 regardless of their stereochemistry (8a−8c vs 8d−8f, or 8h−
8k).85,86 Several of the prepared compounds were tested in a
a functional assay and behaved as antagonists of the hMR.
Values determined using a yeast two-hybrid assay to asses inhibition
of MR interaction with a co-regulator. Moreover, three of them, namely 8b (0.79 nM), 8g (0.08 nM),
2643 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Figure 8.1. General structures of tricyclic scaffolds developed at Eli Lilly that led to compounds with inhibitory constants lower that 500 nM for MR.

and 8h (0.23 nM), with Ki values below 1 nM, demonstrated in from SRC1, PGC1α, PGC1β, and ASC2 co-activators, which
vivo renal protective activity in a rat model of aldosterone- have an extra leucine before the LXXLL motif in the NR-box.
mediated renal disease.85 However, not all LLXXLL-containing peptides were capable of
Compound 8m showed a good selectivity for binding the strong interactions. In the presence of eplerenone the
MR, from 800- to 7500-fold over GR, AR, and PR, and was recruitment of these peptides is blocked, indicating that
selected for a combination therapy with tadalafil for the eplerenone changes the conformation of the MR LBD.
treatment of resistant hypertension.87 Taladafil is a phospho- Li et al. also focused on peptides derived from known co-
diesterase type 5 (PDE5) inhibitor and behaves as a mild activators containing LXXLL motifs (Table 9.1). They also
vasodilator. Authors also indicated that this therapeutic found a preferential binding of the fourth LXXLL motif of
combination would alleviate PDE5-monotherapy resistant steroid receptor co-activator-1 (SRC1-4).7 In contrast, a weaker
erectile dysfuntion. interaction was established for the first motif of SRC1-1 and
An Eli Lilly and Company derivative, LY2623091 (structure SRC3-1 (over 16 μM).7 Interestingly, the X-ray structure of the
not disclosed), entered phase II clinical studies for the MR LBD bound to corticosterone and SRC1-4 (1.95 Å, PDB
treatment of hypertension and chronic kidney disease. ID 2A3I7) suggested two molecular structural features that
Although to the best of our knowledge there is no publication could account for the high affinity of SRC1-4. First, the
that revealed its structure, on the Internet this compound has glutamic acid at position +7 (relative to the first leucine in the
been associated with derivative 8m.88,89 LXXLL motif) that is hydrogen bonded with K782 of MR.
In 2016, Vitae pharmaceuticals explored several linkers Second, the high stability of the SRC1-4 helix due to the
between the tricyclic scaffold and a series of bicyclic moieties existence of several intramolecular hydrogen bonds between Q
(Table 8.1, 8o, 8p, Figure 8.2).70 The selection of the bicyclic +3 and K−3 as well as Q+2 and S−2.
system was based on previous SAR studies, which suggested the In order to identify antagonist peptides able to interact with
1,4 benzoxazin-3-one (8q), 1,3-benzoxazin-2-thione (8r), and the MR in a ligand-selective manner, Yang et al. recently used
several spirooxindoles (8s−8u) as suitable sub-groups.70 two phage libraries, expressing 19mer peptides, to screen 108
Interestingly, an X-ray structure was described for the MR peptides for MR binding in the presence of three different
LBD complex with compound 8q (2.5 Å, PDB ID 5HCV).70 In agonists: aldosterone, cortisol, and deoxycorticosterone (Table
a similar way to previous X-ray structures, there are two 9.2).91 One of the libraries was designed to target the AF-2
hydrogen bonds involving Asn770 and the NH group and region of the MR, and consequently included a central LXXLL
carbonyl oxygen of the benzoxazinone moiety, besides one motif flanked by seven random amino acids on either side. The
more between the carbonyl group and the Thr945 side chain other was a random library created to identify peptides that
(Figure 8.3). In contrast, no hydrogen bond is observed could bind to any site on the MR. The analysis of the 165
between the receptor and the tricyclic structure. peptides using the mammalian two-hybrid assay showed that 18
9. Peptide MR Ligands. The MR LBD, the key regulatory peptides had an enhanced interaction by the addition of the
domain of MR, contains an activation function-2 domain (AF- ligand, one from the random library and 17 from the LXXLL-
2) in addition to the binding pocket for the endogenous constrained phage library (9a−9d).91 Within these latter
ligands. The AF-2 domain has been implicated in the peptides, approximately 50% of them contained the unique
interaction with co-activators that contain multiple LXXLL motif MPXLXXLL. Six of these 18 peptides were selective for
motifs, organized as α-helices. These co-regulators are critical the MR, five of them from the constrained phage library, and
for MR-mediated gene expression and may confer specificity to interacted significantly better in the presence of aldosterone
MR-mediated responses. Thus, there is a great interest in (9e−9g), while the one from the random library (9h) showed
knowing whether different MR ligands can induce distinct MR increased interaction in the presence of cortisol.91 Thus, these
conformations that might lead to different co-regulator studies have demonstrated that different peptides interact
recruitment and ligand-specific gene regulation. differentially with the MR in the presence of different ligands,
Hultman et al. focused on co-activator and co-repressor thus suggesting that agonists can induce different conforma-
peptides and their interaction with the LBD of the MR in the tional changes in the MR that might lead to the recruitment of
presence of various MR ligands.90 They analyzed 50 co- specific co-regulatory proteins.
regulator peptides, derived from 23 co-activators and co- Rogerson et al., with the aim of identifying co-regulatory
repressors, containing the NR-box or CoRNR-box motifs molecules that could exhibit a ligand-specific interaction with
(small peptide motifs that are necessary and sufficient to the MR LBD, screened a yeast-2-hybrid kidney cDNA library in
interact with NRs). Only a few of these peptides showed strong the presence of aldosterone and cortisol.92 A clone encoding
interactions with the MR LBD in the presence of aldosterone the region of the tesmin (metallothionein-like 5) gene that has
or the glucocorticoid cortisol. These include peptides derived two LXXLL motifs provided a 7-fold greater response in the
2644 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Table 8.1. Tricyclic Compounds with Ki ≤ 10 nM for hMR

Figure 8.2. Structures of tricyclic scaffolds developed at Vitae
Pharmaceuticals that led to compounds able to bind to MR LBD.
Competitive binding assay using [3H]-cortisol.

open the venue for the development of selective MR
modulators.

■ CONCLUSIONS
The MR is a member of the nuclear receptor family that plays
an important role in regulating genes involved in cardiovascular
diseases and electrolyte homeostasis. The two currently
marketed MR antagonists, eplerenone and spironolactone,
both with a structure similar to that of steroid hormones, have
proven to be effective in the treatment of hypertension or
congestive heart failure. However, their therapeutic use is
limited due to unwanted side effects. These limitations have
propelled the search of new non-steroidal MR antagonists able
to circumvent these drawbacks. Over the past years this search
has been intensified and has mainly been undertaken by
pharmaceutical companies. In general, the research has started
with a HTS, which allowed the identification of a hit able to
interact with the MR. Next, hit-to-lead optimization processes
were carried out to improve potency and selectivity as well as
pharmacokinetic properties. These medicinal chemistry ap-
proaches have provided a series of scaffolds, such as five- and
six-membered heterocyclic rings or bicyclic and tricyclic
skeletons, able to support key pharmacophore groups in the
right 3D disposition to interact with the MR, thus leading to
novel MR antagonists. Interestingly, several of the non-steroid
derivatives showed excellent potency toward the MR and
selectivity against other nuclear receptors and displayed in vivo
activity.
Recently, X-ray structures describing the MR LBD not only
bound to steroid ligands but also in complex with non-steroidal
compounds have become available. These structures are
valuable tools for the computer-assisted design of new MR
ligands, or to guide the hit to lead optimization process. In fact,
as above indicated, docking studies have proved to be useful to
optimize initial HTS hits, leading to compounds with improved
PK and PD properties. The resolution of complexes of the MR
LBD bound to other families of antagonists could provide
further insight into the binding mode of these compounds.
In vivo studies with the most promising compounds have
shown that MR antagonists are able to reduce blood pressure
and protect against aldosterone-mediated renal and cardiovas-
a
8a−8n: competitive binding assay using [3H]-aldosterone. 8o, 8p: cular injuries. Moreover, some compounds have proved to
MR competitive binding assay using [3H]-cortisol. reduce sex-hormone-related adverse effects and to lower the
incidence of hyperkalemia compared with the marketed steroid-
presence of aldosterone over cortisol. Therefore, tesmin was a like antagonists. Several non-steroidal compounds are currently
ligand-selective co-activator of the hMR, providing further in clinical evaluation for congestive heart failure, hypertension,
evidence of the adoption of ligand-dependent conformations by or diabetic nephropathy. These derivatives belong to different
the MR-LBD. The understanding of these interactions may chemical families and have been designated as 1p, 2k,
2645 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Figure 8.3. (A) Close-up view of the X-ray structure of the MRC808S/S810L-LBD double mutant bound to 8q (cyan) (PDB ID 5HCV). (B)
Superimposition of the X-ray structures of compound 8q (cyan) and spironolactone (orange) bound to the MRC808S/S810L-LBD (PDB IDs 5HCV
and 3VHU, respectively). The hydrogen bonds and water molecules are depicted as yellow dashed lines and red spheres, respectively.

Table 9.1. Peptides Derived from Co-activators with LXXLL Motifs
peptide IC50 (μM)a
SRC2-1 S K G Q T K L L Q L L T C S S 3.9
SRC1-2 T E R H K I L H R L L Q E S S 1.4
SRC2-2 K E K H K I L H R L L Q D S S 2.2
SRC3-2 Q E K H R I L H K L L Q N G N 4.6
SRC1-3 S K D H Q L L R Y L L D K D E 1.6
SRC2-3 K E N A L L R Y L L D K D D 4.8
SRC3-3 K E N N A L L R Y L L D R D D 1.4
SRC1-4 A Q Q K S L L Q Q L L T E 0.9
PGC1α-1 A E E P S L L K K L L L A P A 0.9
PGC1α-2 R R P C S E L L K Y L T T N D 1.1
a
In vitro peptide competition experiments using AlphaScreen Assays (PerkinElmer).

Table 9.2. Peptides Identified as MR Antagonists Using Phage Display
9a V P E P M S M L R A L L S N D D G S G
9b P P P E Q S I L H R L L T A D V S D L
9c L S E T H P L L W T L L S S E G D S M
9d L E E R M P L L S G L L T G T Y L T G
9e D F G P M P L L R S L L E E N I G T G
9f L D H Q F P L L T Q L L R S Y D A G L
9g G E M R M P I L T G L L T S H P Y Q E
9h S C D N S Y C N I R S W F S D R V I S

LY2623091 (structure not disclosed), and MT-3995 (a coactivators, together with allosteric modulators of the MR
Mitsubishi Tanabe Pharma Corporation non-steroidal deriva- action targeting protein−protein interaction, may be interesting
tive in phase II studies for diabetic nephropathy, structure not areas to explore.
disclosed to the best of our knowledge).93 These promising
results have encouraged the search of novel non-steroidal MR
antagonists that overcome the limitations of steroid molecules.
■ AUTHOR INFORMATION
Corresponding Author
Over the past few years, a variety of tissue-specific MR targets *E-mail: mercedes@iqm.csic.es. Telephone: +34 912587478.
with prominent roles in several physiological and pathophysio-
ORCID
logical processes played by MR have been described. Thus, it is
now clear that many of the most important MR target genes are Mercedes Martín-Martínez: 0000-0002-6449-0905
highly tissue-specific. This, together with the similarities of the Notes
MR with other steroid receptors, highlights the importance of The authors declare no competing financial interest.
finding tissue-selective non-steroidal MR antagonists with the Biographies
desired therapeutic potential and diminished adverse effects. ́
Mercedes Martin-Marti ́
nez received her B.Sc. and Ph.D. (1996) in
The determinants of the MR tissue-specific regulation of genes chemistry from Complutense University in Madrid. After her Ph.D.
are unclear, but presumably the process is at least partially she joined the group of Prof. Tom Blundell at Cambridge University
based on differential interaction with co-regulators of tran- (U.K.), where she got expertise in structure-based computer-aided
scription. Therefore, the search of compounds able to bind to drug design. In 1999, she moved back to the Medicinal Chemistry
the MR LBD and modulate the recruitment of different Institute (IQM-CSIC), where she is currently a staff scientific

2646 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

researcher and a member of the peptidomimetics group. Her research School of Medicine at Mount Sinai. His research interest lies in basic
interests focus on the application of molecular modeling tools to the molecular mechanisms of epigenetic control of gene transcription.
design of novel molecular entities able to modulate protein Among his contributions are the discovery of the bromodomain as the
interactions. One of her currently interests is the search of non- acetyl-lysine binding domain (Nature, 1999) and validation of
steroidal modulators of MR. bromodomain proteins as drug targets for cancer and inflammation
Felipe L. Pérez-Gordillo received his B.Sc. in chemistry from the (Cancer Cell 2014). Dr. Zhou received a Ph.D. degree in chemistry at
University of Granada, Spain, in 1997, and became a specialist in Purdue University, did postdoctoral studies at Abbott Laboratories,
clinical biochemistry at Hospital Universitario La Paz, Madrid, in 2004. and has published over 150 research papers. Dr. Zhou is a Director at
He joined the Spanish National Council for Scientific Research New York Structural Biology Center and a fellow of the American
(CSIC) as a research collaborator in 2009. He is currently pursuing a Association for the Advancement of Science (2012).
́
Ph.D. under the supervision of Dr. Mercedes Martin-Marti ́
nez.
a strong interest in drug discovery, especially in small-molecule
He has

inhibitors for MR. His expertise is in the development and synthesis of
■ ACKNOWLEDGMENTS
Supported by grants from Ministerio de Economiá y
druglike compounds and computational modeling. Competitividad (MINECO, Spain; grants BFU2012-39092-
Diego Á lvarez de la Rosa has been a professor of physiology at C02-02, BFU2013-47089-R, and SAF2015-66275-C2-R), Euro-
Universidad de La Laguna (Spain) since 2009. He established his pean Cooperation in Science and Technology (COST) action
research group at the university as a junior group leader in 2005, after ADMIRE (BM-1301), the European Union Seventh Frame-
completing postdoctoral training at Yale University School of work Program “Capacities” (FP7-REGPOT-2012-CT2012-
Medicine (1999−2004). His research focuses on mineralocorticoid 31637-IMBRAIN), and CSIC (201280E096). Y.R. is grateful
hormone actions, with special focus on molecular mechanisms of to CUNY for being a recipient of the CUNY Chancellor’s
receptor modulation and characterization of target genes. Research Fellowship Award for the 2015 - 20162015−2016
́ Academic Year.


Yoel Rodriguez received his B.S. in chemistry from Havana University
in 1995, and his Ph.D. in chemistry/theoretical biophysics at
Complutense University of Madrid, Spain, in 2002 with Dr. Francisco REFERENCES
Montero Carnerero, both summa cum laude. He conducted (1) Arriza, J. L.; Weinberger, C.; Cerelli, G.; Glaser, T. M.; Handelin,
postdoctoral research in computational biophysics with Dr. Roman B. L.; Housman, D. E.; Evans, R. M. Cloning of human
Osman at Mount Sinai School of Medicine (MSSM), New York, from mineralocorticoid receptor complementary DNA: structural and
́
2003 to 2007. In 2008, Rodriguez was appointed Assistant Professor of functional kinship with the glucocorticoid receptor. Science 1987,
237, 268−275.
Physics and Chemistry in the Natural Sciences Department of Hostos
(2) Lifton, R. P.; Gharavi, A. G.; Geller, D. S. Molecular mechanisms
Community College of CUNY, where he is currently Associate of human hypertension. Cell 2001, 104, 545−556.
Professor. He is also a visiting professor at MSSM in the Department (3) Nguyen Dinh Cat, A.; Jaisser, F. Extrarenal effects of aldosterone.
of Pharmacological Science, where he collaborates with Dr. Ming- Curr. Opin. Nephrol. Hypertens. 2012, 21, 147−156.
Ming Zhou. His research focuses on applying computational (4) Chapman, K.; Holmes, M.; Seckl, J. 11Beta-hydroxysteroid
theoretical biophysics methods to investigate molecular mechanisms dehydrogenases: intracellular gate-keepers of tissue glucocorticoid
in biological processes. action. Physiol. Rev. 2013, 93, 1139−1206.
(5) Farman, N.; Rafestin-Oblin, M. E. Multiple aspects of
Guillermo Gerona-Navarro received his B.S. in chemistry from mineralocorticoid selectivity. Am. J. Physiol. Renal Physiol. 2001, 280,
Havana University in 1996, and his Ph.D. in chemistry/medicinal F181−192.
chemistry at Complutense University of Madrid, Spain, in 2002 with (6) Bledsoe, R. K.; Madauss, K. P.; Holt, J. A.; Apolito, C. J.;
Dr. Rosario Gonzalez-Muñiz, both summa cum laude. He conducted Lambert, M. H.; Pearce, K. H.; Stanley, T. B.; Stewart, E. L.; Trump, R.
postdoctoral research with Prof. Samie Jaffrey at Weill Medical College P.; Willson, T. M.; Williams, S. P. A ligand-mediated hydrogen bond
of Cornell University from 2003 to 2006, and with Dr. Ming-Ming network required for the activation of the mineralocorticoid receptor.
Zhou at Mount Sinai School of Medicine (MSSM) from 2007 to 2012, J. Biol. Chem. 2005, 280, 31283−31293.
both in chemical biology. In 2013, Dr. Gerona-Navarro was appointed (7) Li, Y.; Suino, K.; Daugherty, J.; Xu, H. E. Structural and
biochemical mechanisms for the specificity of hormone binding and
assistant professor in the Chemistry Department of Brooklyn College
coactivator assembly by mineralocorticoid receptor. Mol. Cell 2005, 19,
of CUNY. His research laboratory at Brooklyn College focuses on 367−380.
developing chemical probes targeting protein−protein interactions (8) Hasui, T.; Matsunaga, N.; Ora, T.; Ohyabu, N.; Nishigaki, N.;
inside of the cell to investigate the role of these biologically relevant Imura, Y.; Igata, Y.; Matsui, H.; Motoyaji, T.; Tanaka, T.; Habuka, N.;
proteins in human biology and disease. Sogabe, S.; Ono, M.; Siedem, C. S.; Tang, T. P.; Gauthier, C.; De
Rosario González-Muñiz completed a Ph.D. in chemistry from Meese, L. A.; Boyd, S. A.; Fukumoto, S. Identification of benzoxazin-3-
one derivatives as novel, potent, and selective nonsteroidal
Autónoma University in Madrid, Spain (1987), and a post-doctoral
mineralocorticoid receptor antagonists. J. Med. Chem. 2011, 54,
stay at René Descartes University (Paris V, 1988-1990). She currently 8616−8631.
is a staff senior scientific researcher at the Medicinal Chemistry (9) Huyet, J.; Pinon, G. M.; Fay, M. R.; Fagart, J.; Rafestin-Oblin, M.
Institute (IQM-CSIC), where she was the Deputy Director (2005− E. Structural basis of spirolactone recognition by the mineralocorticoid
2011) and is currently the head of the peptidomimetics group. She is a receptor. Mol. Pharmacol. 2007, 72, 563−571.
specialist in peptides, peptidomimetics, and bioactive small-molecules, (10) Geller, D. S.; Farhi, A.; Pinkerton, N.; Fradley, M.; Moritz, M.;
and her recent research interests include the design and synthesis of Spitzer, A.; Meinke, G.; Tsai, F. T.; Sigler, P. B.; Lifton, R. P.
new modulators of protein−protein interactions and of different types Activating mineralocorticoid receptor mutation in hypertension
of ion channels and associated proteins. exacerbated by pregnancy. Science 2000, 289, 119−123.
(11) Fagart, J.; Huyet, J.; Pinon, G. M.; Rochel, M.; Mayer, C.;
Ming-Ming Zhou, Ph.D., is the Dr. Harold and Golden Lamport Rafestin-Oblin, M. E. Crystal structure of a mutant mineralocorticoid
Professor and Chairman of Department of Pharmacological Sciences, receptor responsible for hypertension. Nat. Struct. Mol. Biol. 2005, 12,
and Co-Director of Experimental Therapeutics Institute at Icahn 554−555.

2647 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

(12) Huyet, J.; Pinon, G. M.; Fay, M. R.; Rafestin-Oblin, M. E.; dihydropyridin derivatives. International Patent WO2005/087740,
Fagart, J. Structural determinants of ligand binding to the 2005.
mineralocorticoid receptor. Mol. Cell. Endocrinol. 2012, 350, 187−195. (29) Kuhl, A.; Kolkhof, P.; Heckroth, H.; Schlemmer, K.-H.; Flamme,
(13) Alvarez de la Rosa, D.; Navarro-Gonzalez, J. F.; Giraldez, T. I.; Gigueroa Perez, S.; Gielen-Haertwig, H.; Grosser, R.; Ergüden, J.-
ENaC modulators and renal disease. Curr. Mol. Pharmacol. 2013, 6, K.; Lang, D. 4-Chromenonyl-1,4-dihydropyridines and their use. U.S.
35−43. Patent US2010/022484A1, 2010.
(14) Brilla, C. G.; Weber, K. T. Mineralocorticoid excess, dietary (30) Lavall, D.; Selzer, C.; Schuster, P.; Lenski, M.; Adam, O.;
sodium, and myocardial fibrosis. J. Lab. Clin. Med. 1992, 120, 893− Schäfers, H.-J.; Böhm, M.; Laufs, U. The mineralocorticoid receptor
901. promotes fibrotic remodeling in atrial fibrillation. J. Biol. Chem. 2014,
(15) Pitt, B.; Zannad, F.; Remme, W. J.; Cody, R.; Castaigne, A.; 289, 6656−6668.
Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on (31) Fagart, J.; Wurtz, J. M.; Souque, A.; Hellal-Levy, C.; Moras, D.;
morbidity and mortality in patients with severe heart failure. Rafestin-Oblin, M. E. Antagonism in the human mineralocorticoid
Randomized aldactone evaluation study investigators. N. Engl. J. receptor. EMBO J. 1998, 17, 3317−3325.
Med. 1999, 341, 709−717. (32) Auzou, G.; Fagart, J.; Souque, A.; Hellal-Levy, C.; Wurtz, J. M.;
(16) Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Moras, D.; Rafestin-Oblin, M. E. A single amino acid mutation of Ala-
Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone 773 in the mineralocorticoid receptor confers agonist properties to
post-acute myocardial infarction heart failure eficacy and survival study 11beta-substituted spirolactones. Mol. Pharmacol. 2000, 58, 684−691.
investigators. Eplerenone, a selective aldosterone blocker, in patients (33) Bärfacker, L.; Kolkhof, P.; Schlemmer, K. H.; Grosser, R.;
with left ventricular dysfunction after myocardial infarction. N. Engl. J. Nitsche, A.; Klein, M.; Münter, K.; Albrecht-Küpper, B.; Hartmann, E.
Med. 2003, 348, 1309−1321. Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use there-
(17) Luther, J. M. Is there a new dawn for selective mineralocorticoid of. U.S. Patent US20100136142A1, 2010.
receptor antagonism? Curr. Opin. Nephrol. Hypertens. 2014, 23, 456− (34) Pitt, B.; Kober, L.; Ponikowski, P.; Gheorghiade, M.; Filippatos,
461. G.; Krum, H.; Nowack, C.; Kolkhof, P.; Kim, S.-Y.; Zannad, F. Safety
(18) Gomez-Sanchez, E. P. Third-generation mineralocorticoid and tolerability of the novel non-steroidal mineralocorticoid receptor
receptor antagonists: why do we need a fourth? J. Cardiovasc. antagonist BAY 94−8862 in patients with chronic heart failure and
Pharmacol. 2016, 67, 26−38. mild or moderate chronic kidney disease: a randomized, double-blind
(19) Roscioni, S. S.; de Zeeuw, D.; Bakker, S. J. L.; Lambers trial. Eur. Heart J. 2013, 34, 2453−2463.
Heerspink, H. J. Management of hyperkalaemia consequent to (35) Kolkhof, P.; Delbeck, M.; Kretschmer, A.; Steinke, W.;
mineralocorticoid-receptor antagonist therapy. Nat. Rev. Nephrol. Hartmann, E.; Bärfacker, L.; Eitner, F.; Albrecht-Küpper, B.; Schäfer,
2012, 8, 691−699. S. Finerenone, a novel selective nonsteroidal mineralocorticoid
(20) Vardeny, O.; Claggett, B.; Anand, I.; Rossignol, P.; Desai, A. S.; receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc.
Zannad, F.; Pitt, B.; Solomon, S. D. Incidence, predictors, and Pharmacol. 2014, 64, 69−78.
outcomes related to hypo- and hyperkalemia in patients with severe (36) Bakris, G. L.; Agarwal, R.; Chan, J. C.; Cooper, M. E.;
heart failure treated with a mineralocorticoid receptor antagonist. Circ.: Gansevoort, R. T.; Haller, H.; Remuzzi, G.; Rossing, P.; Schmieder, R.
Heart Failure 2014, 7, 573−579. E.; Nowack, C.; Kolkhof, P.; Joseph, A.; Pieper, A.; Kimmeskamp-
(21) Kolkhof, P.; Nowack, C.; Eitner, F. Nonsteroidal antagonists of Kirschbaum, N.; Ruilope, L. M. Effect of finerenone on albuminuria in
the mineralocorticoid receptor. Curr. Opin. Nephrol. Hypertens. 2015, patients with diabetic nephropathy: A randomized clinical trial. JAMA
24, 417−424. 2015, 314, 884−894.
(22) Piotrowski, D. W. Mineralocorticoid receptor antagonists for the (37) Haller, H.; Bertram, A.; Stahl, K.; Menne, J. Finerenone: a new
treatment of hypertension and diabetic nephropathy. J. Med. Chem. mineralocorticoid receptor antagonist without hyperkalemia: an
2012, 55, 7957−7966. opportunity in patients with CKD? Curr. Hypertens. Rep. 2016, 18,
(23) Dietz, J. D.; Du, S.; Bolten, C. W.; Payne, M. A.; Xia, C.; Blinn, 1−9.
J. R.; Funder, J. W.; Hu, X. A number of marketed dihydropyridine (38) Feng, Y.; Zeng, X.; Fu, P. FInerenone for albuminuria in patients
calcium channel blockers have mineralocorticoid receptor antagonist with diabetic nephropathy. JAMA 2016, 315, 305−306.
activity. Hypertension 2008, 51, 742−748. (39) Filippatos, G.; Anker, S. D.; Böhm, M.; Gheorghiade, M.; Køber,
(24) Arhancet, G. B.; Woodard, S. S.; Dietz, J. D.; Garland, D. J.; L.; Krum, H.; Maggioni, A. P.; Ponikowski, P.; Voors, A. A.; Zannad,
Wagner, G. M.; Iyanar, K.; Collins, J. T.; Blinn, J. R.; Numann, R. E.; F.; Kim, S.-Y.; Nowack, C.; Palombo, G.; Kolkhof, P.; Kimmeskamp-
Hu, X.; Huang, H. C. Stereochemical requirements for the Kirschbaum, N.; Pieper, A.; Pitt, B. A randomized controlled study of
mineralocorticoid receptor antagonist activity of dihydropyridines. J. finerenone vs. eplerenone in patients with worsening chronic heart
Med. Chem. 2010, 53, 4300−4304. failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart
(25) Bärfacker, L.; Kuhl, A.; Hillisch, A.; Grosser, R.; Figueroa-Pérez, J. 2016, 37, 2105−2114.
S.; Heckroth, H.; Nitsche, A.; Ergüden, J.-K.; Gielen-Haertwig, H.; (40) Amazit, L.; Le Billan, F.; Kolkhof, P.; Lamribet, K.;
Schlemmer, K.-H.; Mittendorf, J.; Paulsen, H.; Platzek, J.; Kolkhof, P. Viengchareun, S.; Fay, M. R.; Khan, J. A.; Hillisch, A.; Lombès, M.;
Discovery of BAY 94−8862: A nonsteroidal antagonist of the Rafestin-Oblin, M.-E.; Fagart, J. Finerenone impedes aldosterone-
mineralocorticoid receptor for the treatment of cardiorenal diseases. dependent nuclear import of the mineralocorticoid receptor and
ChemMedChem 2012, 7, 1385−1403. prevents genomic recruitment of ateroid recpetor coactivator-1. J. Biol.
(26) Arhancet, G. B.; Woodard, S. S.; Iyanar, K.; Case, B. L.; Chem. 2015, 290, 21876−21889.
Woerndle, R.; Dietz, J. D.; Garland, D. J.; Collins, J. T.; Payne, M. A.; (41) Brandish, P., Fraley, E.; Mark, E.; Hershey, J. C.; Steem, J. T.
Blinn, J. R.; Pomposiello, S. I.; Hu, X.; Heron, M. I.; Huang, H.-C.; Mineralocorticoid receptor modulators. International Patent
Lee, L. F. Discovery of novel cyanodihydropyridines as potent WO2009/078934A1, 2009.
mineralocorticoid receptor antagonists. J. Med. Chem. 2010, 53, 5970− (42) Arai, K.; Homma, T.; Morikawa, Y.; Ubukata, N.; Tsuruoka, H.;
5978. Aoki, K.; Ishikawa, H.; Mizuno, M.; Sada, T. Pharmacological profile of
(27) Fagart, J.; Hillisch, A.; Huyet, J.; Bärfacker, L.; Fay, M.; Pleiss, CS-3150, a novel, highly potent and selective non-steroidal
U.; Pook, E.; Schäfer, S.; Rafestin-Oblin, M.-E.; Kolkhof, P. A new mineralocorticoid receptor antagonist. Eur. J. Pharmacol. 2015, 761,
mode of mineralocorticoid receptor antagonism by a potent and 226−234.
selective nonsteroidal molecule. J. Biol. Chem. 2010, 285, 29932− (43) Canne, B. L.; Chen, J.; Dalrymple, L. E.; Flatt, B. T.; Forsyth, T.
29940. P.; Gu, X. H.; Mac, M. B.; Mann, G.; Mann, L. W.; Martin, R. Pyrrole
(28) Ergüden, J.-K. D.; Kolkhof, P. D.; Sandner, P. D.; Kuhl, A. D.; derivatives as pharmaceutical agents. International Patent WO2006/
Stasch, J.-P. D.; Pook, E. D.; Schlemmer, K.-H. D. Fluorenone 1,4- 012642, 2006.

2648 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

(44) Nuss, J.; Williams, M.; Mohan, R.; Martin, R.; Wang, T. L.; Aoki, (60) Yang, C.; Balsells, J.; Chu, H. D.; Cox, J. M.; Crespo, A.; Ma, X.;
K.; Tsuruoka, H.; Hayashi, N.; Homma, T. Atropisomers of Contino, L.; Brown, P.; Gao, S.; Zamlynny, B.; Wiltsie, J.; Clemas, J.;
(hydroxyalkyl) pyrrole derivatives. International Patent WO2010/ Lisnock, J.; Gibson, J.; Zhou, G.; Garcia-Calvo, M.; Bateman, T. J.;
042622A1, 2010. Tong, V.; Xu, L.; Crook, M.; Sinclair, P.; Shen, H. C. Discovery of
(45) Nuss, J.; Williams, M.; Mohan, R.; Martin, R.; Wang, T. L.; benzimidazole oxazolidinediones as novel and selective nonsteroidal
Tsuruoka, H.; Aoki, K.; Honzumi, M.; Asoh, Y.; Saito, K. 1- mineralocorticoid receptor antagonists. ACS Med. Chem. Lett. 2015, 6,
Phenylpyrrole compounds. International Patent WO2010/042626, 461−465.
2010. (61) Futatsugi, K.; Piotrowski, D. W.; Casimiro-Garcia, A.; Robinson,
(46) Arai, K.; Tsuruoka, H.; Homma, T. CS-3150, a novel non- S.; Sammons, M.; Loria, P. M.; Banker, M. E.; Petersen, D. N.;
steroidal mineralocorticoid receptor antagonist, prevents hypertension Schmidt, N. J. Design and synthesis of aryl sulfonamide-based
and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur. J. nonsteroidal mineralocorticoid receptor antagonists. Bioorg. Med.
Pharmacol. 2015, 769, 266−273. Chem. Lett. 2013, 23, 6239−6242.
(47) Meyers, M. J.; Arhancet, G. B.; Hockerman, S. L.; Chen, X.; (62) Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogDoct:
Long, S. A.; Mahoney, M. W.; Rico, J. R.; Garland, D. J.; Blinn, J. R.; A tool for lipophilicity determination in drug discovery. 2. Basic and
Collins, J. T.; Yang, S.; Huang, H.-C.; McGee, K. F.; Wendling, J. M.; neutral compounds. J. Med. Chem. 2001, 44, 2490−2497.
Dietz, J. D.; Payne, M. A.; Homer, B. L.; Heron, M. I.; Reitz, D. B.; Hu, (63) Katayama, S.; Hori, S.; Hasegawa, F.; Suzuki, K. Biaryl amide
X. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl- derivative or pharmaceutically acceptable salt thereof. U.S. Patent
3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic Acid (PF- US2013/116227A1, 2013.
3882845), an orally efficacious mineralocorticoid receptor (MR) (64) Boyer, S.; Guo, X.; Wu, D.; Wu, F. Pyridyl ureas as
antagonist for hypertension and nephropathy. J. Med. Chem. 2010, 53, mineralocorticoid receptor antagonists. International Patent
5979−6002. WO2012/064631A1, 2012.
(48) Arhancet, G. B.; Casimiro-Garcia, A.; Chen, X.; Hepworth, D.; (65) Neel, D. A.; Brown, M. L.; Lander, P. A.; Grese, T. A.; Defauw,
Meyers, M. J.; Piotrowski, D. W.; Raheja, R. K. 4,5-Dihydro-1h- J. M.; Doti, R. A.; Fields, T.; Kelley, S. A.; Smith, S.; Zimmerman, K.
pyrazole compounds and their pharmaceutical uses. International M.; Steinberg, M. I.; Jadhav, P. K. 3,3-Bisaryloxindoles as
Patent WO2010/116282 A1, 2010. mineralocorticoid receptor antagonists. Bioorg. Med. Chem. Lett.
(49) Meyers, M. J.; Arhancet, G. B.; Chen, X.; Hockerman, S.; Long, 2005, 15, 2553−2557.
S. A.; Mahoney, M. W.; Reitz, D. B.; Rico, J. G. Pyrazoline compounds. (66) Bell, M. G.; Gavardinas, K.; Gernert, D. L.; Grese, T. A.; Jadhav,
U.S. Patent US2008/0167294 A1, 2008. P. K.; Lander, P. A.; Steinberg, M. I. Indole-derivative modulators of
(50) Casimiro-Garcia, A.; Piotrowski, D. W.; Ambler, C.; Arhancet, steroid hormone nuclear receptors. International Patent WO2004/
G. B.; Banker, M. E.; Banks, T.; Boustany-Kari, C. M.; Cai, C.; Chen, 067529A1, 2004.
X.; Eudy, R.; Hepworth, D.; Hulford, C. A.; Jennings, S. M.; Loria, P. (67) Bell, M. G.; Gernert, D. L.; Grese, T. A.; Belvo, M. D.;
M.; Meyers, M. J.; Petersen, D. N.; Raheja, N. K.; Sammons, M.; She, Borromeo, P. S.; Kelley, S. A.; Kennedy, J. H.; Kolis, S. P.; Lander, P.
L.; Song, K.; Vrieze, D.; Wei, L. Identification of (R)-6-(1-(4-cyano-3- A.; Richey, R.; Sharp, V. S.; Stephenson, G. A.; Williams, J. D.; Yu, H.;
methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-me thox- Zimmerman, K. M.; Steinberg, M. I.; Jadhav, P. K. (S)-N-{3-[1-
ynicotinic acid, a highly potent and selective nonsteroidal Cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methane-
mineralocorticoid receptor antagonist. J. Med. Chem. 2014, 57, sulfonamide: A potent, nonsteroidal, functional antagonist of the
4273−4288. mineralocorticoid receptor. J. Med. Chem. 2007, 50, 6443−6445.
(51) Dehring, K. A.; Workman, H. L.; Miller, K. D.; Mandagere, A.; (68) Cernak, T. A.; Dykstra, K. D. Mineralocorticoid receptor
Poole, S. K. Automated robotic liquid handling/laser-based neph- antagonists. International Patent WO2014/014794A2, 2014.
elometry system for high throughput measurement of kinetic aqueous (69) Michellys, P. Y.; Pei, W.; Petrassi, H. M.; Richmond, W.
solubility. J. Pharm. Biomed. Anal. 2004, 36, 447−456. Compounds and compositions as modulators of steroid hormone
(52) Brandish, P. E.; Fraley, M. E.; Hershey, J. C.; Steen, J. T. nuclear receptors. International Patent WO2006/015259, 2006.
Mineralocorticoid receptor modulators. International Patent (70) Lotesta, S. D.; Marcus, A. P.; Zheng, Y.; Leftheris, K.; Noto, P.
WO2008/118319A2, 2008. B.; Meng, S.; Kandpal, G.; Chen, G.; Zhou, J.; McKeever, B.;
(53) Brandish, P. E.; Chen, H.; Szczerba, P.; Hershey, J. C. Bukhtiyarov, Y.; Zhao, Y.; Lala, D. S.; Singh, S. B.; McGeehan, G. M.
Development of a simplified assay for determination of the Identification of spirooxindole and dibenzoxazepine motifs as potent
antimineralocorticoid activity of compounds dosed in rats. J. mineralocorticoid receptor antagonists. Bioorg. Med. Chem. 2016, 24,
Pharmacol. Toxicol. Methods 2008, 57, 155−160. 1384−1391.
(54) Yang, C.; Shen, H. C.; Wu, Z.; Chu, H. D.; Cox, J. M.; Balsells, (71) Iijima, T.; Yamamoto, Y.; Akatsuka, H.; Kawaguchi, T.
J.; Crespo, A.; Brown, P.; Zamlynny, B.; Wiltsie, J.; Clemas, J.; Gibson, Benzoxazines and related nitrogen-containing heterobicyclic com-
J.; Contino, L.; Lisnock, J.; Zhou, G.; Garcia-Calvo, M.; Bateman, T.; pounds useful as mineralocorticoid receptor modulating agents.
Xu, L.; Tong, X.; Crook, M.; Sinclair, P. Discovery of novel International Patent WO2007/089034, 2007.
oxazolidinedione derivatives as potent and selective mineralocorticoid (72) Fukumoto, S.; Matsunaga, N.; Ohra, T.; Ohyabu, N.; Hasui, T.;
receptor antagonists. Bioorg. Med. Chem. Lett. 2013, 23, 4388−4392. Motoyaji, T.; Siedem, C. S.; Tang, T. P.; Demeese, L. A.; Gauthier, C.
(55) Shen, H.; Cox, J. M.; Yang, C.; Wu, Z. Mineralocorticoid Fused heterocyclic compounds and their use as mineralocorticoid
receptor antagonists. International Patent WO2013/055606, 2013. receptor ligands. U.S. Patent US2009/0253687, 2009.
(56) PathHunter protein−protein interaction cell-based assay that (73) Hasui, T.; Ohra, T.; Ohyabu, N.; Asano, K.; Matsui, H.;
measures the ability of compounds to antagonize full-length human Mizukami, A.; Habuka, N.; Sogabe, S.; Endo, S.; Siedem, C. S.; Tang,
MR binding to a coactivator peptide, DiscoverX. T. P.; Gauthier, C.; De Meese, L. A.; Boyd, S. A.; Fukumoto, S. Design,
(57) Shen, H.; Cox, J. M.; Chu, H. D. Mineralocorticoid receptor synthesis, and structure−activity relationships of dihydrofuran-2-one
antagonists. International Patent WO2013/055608, 2013. and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based
(58) Shen, H.; Yang, C.; Cox, J. M.; Liu, K. Mineralocorticoid mineralocorticoid receptor antagonists. Bioorg. Med. Chem. 2013, 21,
receptor antagonist. International Patent WO2013/055607, 2013. 5983−5994.
(59) Cox, J. M.; Chu, H. D.; Yang, C.; Shen, H. C.; Wu, Z.; Balsells, (74) Fukumoto, S.; Ohyabu, N.; Ohra, T.; Sugimoto, T.; Hasui, T.;
J.; Crespo, A.; Brown, P.; Zamlynny, B.; Wiltsie, J.; Clemas, J.; Gibson, Fuji, K.; SIEDEM, C. S.; Gauthier, C. Pyrazole compounds. U.S.
J.; Contino, L.; Lisnock, J.; Zhou, G.; Garcia-Calvo, M.; Bateman, T.; Patent US2010/0094000, 2010.
Xu, L.; Tong, X.; Crook, M.; Sinclair, P. Mineralocorticoid receptor (75) Hasui, T.; Ohyabu, N.; Ohra, T.; Fuji, K.; Sugimoto, T.;
antagonists: Identification of heterocyclic amide replacements in the Fujimoto, J.; Asano, K.; Oosawa, M.; Shiotani, S.; Nishigaki, N.;
oxazolidinedione series. Bioorg. Med. Chem. Lett. 2014, 24, 1681−1684. Kusumoto, K.; Matsui, H.; Mizukami, A.; Habuka, N.; Sogabe, S.;

2649 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650
Journal of Medicinal Chemistry Perspective

Endo, S.; Ono, M.; Siedem, C. S.; Tang, T. P.; Gauthier, C.; De Meese,
L. A.; Boyd, S. A.; Fukumoto, S. Discovery of 6-[5-(4-fluorophenyl)-3-
methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective
nonsteroidal mineralocorticoid receptor antagonists. Bioorg. Med.
Chem. 2014, 22, 5428−5445.
(76) Casimiro-Garcia, A.; Futatsugi, K.; Piotrowski, D. W. Morpho-
line compounds as mineralocorticoid receptor antagonists. Interna-
tional Patent WO2011/141848A1, 2011.
(77) Higuchi, R.; Zhi, L.; Karanewsky, D. Mineralocorticoid receptor
modulator compounds, processes for their preparation, and their uses.
U.S. Patent US2007/185102A1, 2007.
(78) Higuchi, R.; Zhi, L.; Adams, M.; Liu, Y.; Karanewsky, D.
Mineralocorticoid receptor modulator compounds, processes for their
preparation, and their uses. U.S. Patent US2007/197520A1, 2007.
(79) Nariai, T.; Fujita, K.; Mori, M.; Katayama, S.; Hori, S.; Matsui,
K. SM-368229, a novel selective and potent non-steroidal
mineralocorticoid receptor antagonist with strong urinary Na+
excretion activity. J. Pharmacol. Sci. 2011, 115, 346−353.
(80) Takahashi, Y.; Awai, N.; Akatsuka, H.; Kawaguchi, T.; Iijima, T.
Fused bicyclic compound. European Patent EP2179994A1, 2010.
(81) Jiang, C.-S.; Zhou, R.; Gong, J.-X.; Chen, L.-L.; Kurtán, T.;
Shen, X.; Guo, Y.-W. Synthesis, modification, and evaluation of (R)-
de-O-methyllasiodiplodin and analogs as nonsteroidal antagonists of
mineralocorticoid receptor. Bioorg. Med. Chem. Lett. 2011, 21, 1171−
1175.
(82) Coghlan, M. J.; Jadhav, P. K.; Droste, J. J.; Green, J. E.;
Matthews, D. P. Tricyclic steroid hormone nuclear receptor
modulators. World Patent WO2005/066153A1, 2005.
(83) Coghlan, M. J.; Green, J. E.; Grese, T. A.; Jadhav, P. K.;
Matthews, D. P.; Steinberg, M. I.; Fales, K. R.; Bell, M. G. Tricyclic
steroid hormone nuclear receptor modulators. World Patent
WO2004/052847A2, 2004.
(84) Gavardinas, K.; Green, J. E.; Jadhav, P. K.; Matthews, D. P.
Tryciclic steroid hormone nuclear receptor modulators. World Patent
WO2005/066161A1, 2005.
(85) Gavardinas, K.; Jadhav, P. K. 6H-Dibenzo[B,E]oxepine derived
nonsteroidal mineralocorticoid receptor antagonists. World Patent
WO2009/085584A1, 2009.
(86) Coates, D. A.; Gavardinas, K.; Jadhav, P. K. Mineralocorticoid
receptor antagonist and methods of use. World Patent WO2010/
104721A1, 2010.
(87) Kowala, M. C. Combination therapy for resistant hypertension.
World Patent WO2015/130568 2015.
(88) http://www.chemspider.com/Chemical-Structure.29361352.
html (accessed Nov 18, 2016).
(89) http://www.chemicalregister.com/LY2623091/Suppliers/
pid705106.htm (accessed Nov 18, 2016).
(90) Hultman, M. L.; Krasnoperova, N. V.; Li, S.; Du, S.; Xia, C.;
Dietz, J. D.; Lala, D. S.; Welsch, D. J.; Hu, X. The ligand-dependent
interaction of mineralocorticoid receptor with coactivator and
corepressor peptides suggests multiple activation mechanisms. Mol.
Endocrinol. 2005, 19, 1460−1473.
(91) Yang, J.; Chang, C.-y.; Safi, R.; Morgan, J.; McDonnell, D. P.;
Fuller, P. J.; Clyne, C. D.; Young, M. J. Identification of ligand-
selective peptide antagonists of the mineralocorticoid receptor using
phage display. Mol. Endocrinol. 2011, 25, 32−43.
(92) Rogerson, F. M.; Yao, Y.-Z.; Young, M. J.; Fuller, P. J.
Identification and characterization of a ligand-selective mineralocorti-
coid receptor coactivator. FASEB J. 2014, 28, 4200−4210.
(93) Clinical trials information: https://clinicaltrials.gov/ct2/show/
NCT02676401 (accessed Dec 19, 2016).

2650 DOI: 10.1021/acs.jmedchem.6b01065
J. Med. Chem. 2017, 60, 2629−2650